

NUCLEAR REGULATORY COMMISSION

ORIGINAL

In the Matter of:

BRIEFING ON: SECY-81-232 -- COMMENTS ON THE
EPA-PROPOSED GUIDANCE FOR OCCUPATIONAL EXPOSURES

DATE: June 10, 1981 PAGES: I thru 64

AT: Washington, D. C.

ALDERSON  REPORTING

400 Virginia Ave., S.W. Washington, D. C. 20024

Telephone: (202) 554-2345

8106260 167

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES OF AMERICA
NUCLEAR REGULATORY COMMISSION

BRIEFING ON SECY-81-232 - COMMENTS ON THE EPA-PROPOSED
GUIDANCE FOR OCCUPATIONAL EXPOSURES

PUBLIC MEETING

Nuclear Regulatory Commission
Room 1130
1717 H Street, N. W.
Washington, D. C.

Wednesday, June 10, 1981

The Commission met, pursuant to notice, at

2:05 p.m.

PRESENT:

- JOSEPH M. HENDRIE, Chairman of the Commission
- VICTOR GILINSKY, Commissioner
- PETER A. BRADFORD, Commissioner
- JOHN F. AHEARNE, Commissioner

ALSO PRESENT:

- S. CHILK
- F. ARSENAULT
- Y. SHLOMO
- J. BECKER
- B. ALEXANDER
- B. DAKER
- H. THORNBURG
- C. WILLIS
- C. ONG
- B. KREGER
- R. CUNNINGHAM
- D. RATHBUN
- S. TRUBATCH

* * *

DISCLAIMER

This is an unofficial transcript of a meeting of the United States Nuclear Regulatory Commission held on 6-10-81 in the Commission's offices at 1717 H Street, N. W., Washington, D. C. The meeting was open to public attendance and observation. This transcript has not been reviewed, corrected, or edited, and is in any event incomplete.

The transcript is intended solely for general informational purposes. As provided by 10 CFR 9.103, it is not part of the formal or informal record or decision of the matters discussed. Expressions of opinion in this transcript do not necessarily reflect final determinations or beliefs. No pleading or other paper may be filed with the Commission in any proceeding as the result of or addressed to any statement or argument contained herein, except as the Commission may authorize.

P R O C E E D I N G S

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CHAIRMAN HENDRIE: Why don't we get started.

The Commission meets this afternoon to hear from the staff on its comments on the EPA-proposed guidance for occupational exposures.

Frank, I take it you will have a lead for the staff.

MR. ARSENAULT: Yes.

CHAIRMAN HENDRIE: Let's go ahead.

MR. ARSENAULT: There are two sets of documents available against which my presentation will be played. I believe that both of these have been made available in sufficient numbers prior to the meeting. One is a matrix which illustrates the comparison between the proposed EPA standard and the ICRP approach to dose limitations, the current 10 C.F.R. 20, and the majority and minority staff views.

COMMISSIONER GILINSKY: There are two minority staff views.

MR. ARSENAULT: The majority and the minority staff views. Yes, there are two minority staff views.

The other documents simply are copies of the slides that I will use to assist in the presentation.

COMMISSIONER AHEARNE: When you are going through the presentation would it be possible for you to identify

1 any areas in which there were significant issues raised or
2 disagreements expressed in the meetings that were held
3 around the country in which NRC participated?

4 MR. ARSENAULT: Yes. Dr. Robert Alexander was the
5 NRC representative during the hearings. He is prepared to
6 address the comments that were received by EPA during those
7 hearings.

8 I can summarize by indicating that the comments
9 were largely critical. They ran the full gamut from the
10 opinion that the standard was too lenient to those who felt
11 that it was too stringent. I believe there were no comments
12 at the hearings that were in support of the standard. Dr.
13 Alexander will be prepared to give you additional details
14 with regard to the hearings.

15 I think that the comments made during the hearings
16 were so varied that it would be difficult for me to capture
17 those points during the presentation. But certainly I will
18 address the major issues that are involved in the standard.

19 (Slide presentation.)

20 If we could have the first slide.

21 The first four slides in fact list the principal
22 recommendations and the principal items in the proposed EPA
23 guidance. They are that any exposures should be justified
24 by the benefits to be accrued from the activities within
25 which they are experienced and that should include

1 consideration of non-radiation alternatives, for example,
2 coal in the event of nuclear power, ionization versus
3 photoelectric smoke detectors, and that sort of thing. This
4 item is held in common with the ICRP approach, I might point
5 out.

6 The second item in the proposed guidance is there
7 should be assurance that collective doses are ALARA. I
8 would point to the use of the word "collective" in this
9 case. This is a consideration which would be applied when
10 considering ALARA as opposed to the individual worker dose
11 as well. It is an overriding consideration in this issue.

12 The second slide, please.

13 Another item is that doses should conform to the
14 radiation protection guides. These are the limits that are
15 to be imposed. This is the first major change from previous
16 guidance which is that the effective dose equivalent should
17 be combined internal and external exposure. This is at the
18 level of five rem per year.

19 In calculating the effective dose equivalent, the
20 external dose would be combined with weighted internal organ
21 doses.

22 In addition to this overall five rem per year
23 limit, there are additional limits imposed on individual
24 organs. The dose limit that would be derived from
25 application of the weighting factors would be large enough

1 to make at least conceivable the incidence of non-stochastic
2 effects, that is direct somatic effects.

3 The limit applied by the proposed EPA guidance for
4 that purpose was 30 rem to any organ with five rem on the
5 gonads.

6 The equivalent ICRP approach to that problem was
7 to apply a limit of 50 rem to the individual organs.

8 COMMISSIONER AHEARNE: Do we currently have any
9 similar limit maximum other than limits on individuals
10 organs?

11 MR. ARSENAULT: Not the equivalent of this. The
12 approach in the current regulations is to apply limits on
13 individual organs, a critical organ concept, and that
14 prevents you from getting to these ranges.

15 I would note in passing that the organ weighting
16 factors in the proposed EPA guidance are different from
17 those of ICRP 26.

18 Next slide, please.

19 Another item in the guidance is the concept of a
20 three-tier system of graded radiation protection actions.
21 As written they would impose requirements for a three-tiered
22 system and they specify the protection requirements for each
23 of these categories and in addition apply a 100 rem lifetime
24 dose limit.

25 The staff view on both of these is that there

1 should be no lifetime dose limit. With regard to the graded
2 radiation protection actions we favor a multi-tiered system
3 consisting of reference levels, but feel that the
4 requirements should be left for development in regulations
5 rather than being included in the guides.

6 COMMISSIONER GILINSKY: Are you going to go into
7 these in detail?

8 MR. ARSENAULT: I will come back to the major
9 issues and discuss them further later on. That would be one
10 of them, yes.

11 The proposed guidance then establishes
12 radioactivity intake factors which are the quantitative
13 limits on the radionuclides to be absorbed into the body,
14 which if absorbed into the body would produce organ doses
15 equivalent to five rem.

16 COMMISSIONER AHEARNE: These are applied to the
17 individual isotopes?

18 MR. ARSENAULT: Individual isotopes, yes.

19 Another principal issue, which I will return to
20 later, is that in the guidance it is recommended that if an
21 RIF turns out to be higher than the limits currently in use
22 as a result of applying the weighting factors in the
23 guidance, that the lower of the two values, that is the
24 current value, would continue to be applied.

25 I will address that later. That is an item in

1 which the majority staff does not agree.

2 The sixth item in the guidance is that there is a
3 requirement that limits be established below the radiation
4 protection guides in the RIFs. This is a requirement. The
5 majority staff considers that this is an ALARA issue as
6 distinct from an occupational dose limit issue. I will
7 address that again.

8 COMMISSIONER GILINSKY: Let me ask you, is any of
9 this affected by the recalculation of the Hiroshima data?

10 MR. ARSENAULT: No. No, it is not affected.

11 COMMISSIONER AHEARNE: You are going to address
12 that?

13 MR. ARSENAULT: I will address the issue, yes,
14 unless you would prefer I address it now. I guess it would
15 be better if we got through the description of the guidance
16 before addressing that issue.

17 The proposed guidance suggests the limit for
18 minors of one/tenth the limits for adults. This approach is
19 shared by the current requirements as well as the ICRP
20 approach.

21 Exposure limits for the unborn, the question of
22 the additional sensitivity of the fetus. EPA proposes four
23 alternatives for comment and does not take a position on
24 which is to be preferred.

25 The majority staff view is that we should continue

1 with the current NRC policy that informed consent would be
2 the way to establish the protection for the unborn rather
3 than applying explicit additional requirements in the guide
4 or the regulations.

5 The ninth and last major recommendation in the
6 guidance is that special planned exposures which exceed the
7 limits should require a prior notification to the regulatory
8 authority, public disclosure of the requirement and
9 case-by-case decisions.

10 The staff view on this is that such a procedure
11 would not be responsive to the need for immediate action
12 which is generally the context in which these requirements
13 arise. We do believe that some general guidance should be
14 provided by regulatory authority in advance and that
15 disclosure on the event should be required, but the
16 procedures prescribed in EPA guidance do not seem to reflect
17 the realities of the situation.

18 Slide five, please.

19 Briefly comparing the current proposed guidance
20 with the earlier FRC guidance and the current 10 C.F.R. Part
21 20, which is based on that guidance, the principal
22 differences then are that the external and internal doses
23 are to be combined for dose limitations.

24 This is regarded as a higher standard of
25 protection and a stricter level of control than we now have

1 and compares to the five rem per year at three per quarter,
2 but conditioned upon the formula of five times the age minus
3 18 lifetime limitation or career limitation. Wherein if the
4 records of the individual were available permitting the
5 calculation of his career dose, the formula was what
6 provided the principal limit.

7 COMMISSIONER GILINSKY: What is an internal dose?

8 MR. ARSENAULT: You mean what does the phrase
9 refer to?

10 COMMISSIONER GILINSKY: Yes.

11 MR. ARSENAULT: It refers to doses to individual
12 organs based on the deposition in the body of
13 radionuclides. It is usually a calculated dose.

14 It would probably be easier to explain that by a
15 comparison.

16 The external dose is the dose to the body
17 resulting from external sources of radiation, as when you
18 are in a radiation field.

19 The other form of radiation exposure is the
20 ingestion or inhalation of radionuclides and their
21 deposition ---

22 COMMISSIONER GILINSKY: That is what the internal
23 dose refers to.

24 MR. ARSENAULT: --- and the internal dose is that
25 latter. Right.

1 COMMISSIONER GILINSKY: Don't we combine those now?

2 MR. ARSENAULT: No, they are not combined now.

3 You have a limit for an external dose of five rem per year
4 at three rem per quarter and 5 rem to the minus 18, plus
5 separately there is a limit of 15 rem, or in the case of
6 some organs 30 rem, from internal exposure.

7 COMMISSIONER AHEARNE: Is that an annual, one-time
8 dose?

9 MR. ARSENAULT: That is an annual.

10 COMMISSIONER AHEARNE: But there is no limit then
11 on the ---

12 MR. ARSENAULT: There is no combination of the
13 two. So it is at least theoretically possible to get five
14 rem in one year from an external source and additional
15 exposure to individual organs from internally deposited
16 radionuclides. That is why it is considered that the
17 combination represents a higher standard of protection.

18 The 100 rem lifetime limit proposed in the EPA
19 guidance is as compared to the career limitaton of five
20 times the age minus 18 in the current requirements.

21 COMMISSIONER GILINSKY: How many people in
22 industry today have gone past the hundred rem limit?

23 MR. ARSENAULT: I don't know the answer to that.
24 Does anyone here know?

25 MR. ALEXANDER: There are very few, a handful.

1 COMMISSIONER AHEARNE: Are the records good enough
2 to know?

3 COMMISSIONER GILINSKY: We don't really know. But
4 you think it is a rather small number?

5 MR. ALEXANDER: It is a small number. In the DOE
6 labs there are some that if you include the internal dose
7 from plutonium and things like that the total dose has
8 already gone over 100 rem.

9 COMMISSIONER GILINSKY: Does that include doses
10 received early in the program?

11 MR. ALEXANDER: Yes.

12 COMMISSIONER GILINSKY: A better point to fix on
13 might be doses received from, say, the fifties or sixties
14 on, and I assume things would tighten up a bit. I guess I
15 am trying to understand why a hundred is limiting and why
16 you feel that is a constraining number.

17 MR. ALEXANDER: The EPA selected that number. The
18 amount of dose allowed now for, say, a 50-year career to
19 make the arithmetic easy would be 250 rem. Using the risk
20 factors from the Bier Report and other publications that
21 leads to what some people consider to be a somewhat high
22 risk. For example, the cancer incidents using these risk
23 factors among people getting five rems per year every year
24 during a working lifetime would be about seven percent.

25 The EPA people felt that that was too high and

1 they wanted a reduction in the lifetime risk and therefore
2 they chose 100 rems as a lifetime limit as a way to achieve
3 that.

4 COMMISSIONER GILINSKY: But I gather that the NRC
5 staff feels that is too low a limit.

6 MR. ARSENAULT: We feel that the benefits to be
7 derived from the application of such a limit do not
8 compensate for the impact that it might have on some
9 individuals.

10 Again, the principle of informed consent might
11 apply here. A hundred rem lifetime level represents 20
12 years at the full limit of five rem.

13 I should point out, first of all, that this would
14 only apply to a very limited number of individuals.

15 COMMISSIONER GILINSKY: That is what I am trying
16 to get at. Would it in fact impact anybody?

17 MR. ARSENAULT: If it would not impact anybody,
18 then one could argue that it is irrelevant and not a useful
19 limitation.

20 COMMISSIONER GILINSKY: How many people would it
21 impact?

22 MR. ARSENAULT: Well, if we have now a few, a very
23 few people who are over the 100 rem lifetime limit, it would
24 impact those. I didn't get a number so I can't give it to
25 you. It is principally the impact on the worker's sense of

1 security and whether or not he feels he has a career if he
2 is in one of the higher risk areas of this occupation.

3 COMMISSIONER GILINSKY: I would have thought one
4 would want to limit at an earlier age.

5 MR. ARSENAULT: That is another aspect of this.
6 First of all, the 100 rem lifetime limit does introduce an
7 element of insecurity into the job environment. Secondly,
8 why 100 rem? The incremental risk from 95 to 96 and 99 to
9 100 is no different than the incremental risk from 100 to
10 101 or 105 to 106.

11 COMMISSIONER GILINSKY: Well, that is true.

12 MR. ARSENAULT: It is true across the full
13 spectrum of exposure. So that in dealing with the
14 incremental level we don't see any particular reason for
15 choosing 100 rem.

16 I guess that was the final argument.

17 COMMISSIONER AHEARNE: There is another aspect.

18 MR. ARSENAULT: There is another aspect, yes.

19 COMMISSIONER AHEARNE: You remember that Tamplin
20 in one of his petitions had raised just that sort of point
21 and had suggested it might be more appropriate to have a
22 lower annual limit for younger people and then raising it
23 for higher annual limit as age went up. I guess the NCRP
24 has begun to look at that and to see whether taking into
25 account some sort of age risk and see if you wouldn't get a

1 different approach.

2 MR. ARSENAULT: There is a qualitative argument
3 that it is likely that this limit would be reached only by
4 people who are already entering a age sector where the risk
5 is diminishing. It is 20 at these and it is not expected
6 that an individual would get five rem per year. But even if
7 he were at that high level of exposure it would be a 20-year
8 period before he absorbed 100 rem at which point he is
9 entering an age when the risk might be reducing but that is
10 a qualitative argument. It is a subjective decision.

11 COMMISSIONER AHEARNE: I think probably an
12 adequate summary is there is no good analytic base for 100,
13 250, 200, 150 and ---

14 COMMISSIONER GILINSKY: Well, but that is true of
15 5 and 30 and 15 and so on, isn't it?

16 COMMISSIONER AHEARNE: Well, as Bob was saying,
17 you can provide risk estimates to fit all of those, but when
18 you try to ask the question of what is the impact? When you
19 talked about the higher numbers, I think that the potential
20 candidates are very small and the industry's records aren't
21 probably good enough to really pick up that small number.

22 When you start getting down to things like 5 or
23 10, yes, you have got a very large number of people who
24 would be impacted. When you get into the 100, 150, 200 and
25 250 region you are talking about a very, very small

1 population who would fall into that category.

2 MR. ARSENAULT: You rapidly reach the point where
3 you must deal in subjective considerations here. But if you
4 accept a 50-year career period as distinct from a 20-year
5 career period, you are talking about the difference between
6 a 100 rem limit and a 250 rem limit, which with the linear
7 theory it represents a factor of two and a half in risk.

8 I would suggest to you that factors on that order
9 in the risk equations seem to be minor variations when
10 considered with the variation in risk that people face from
11 the various sources.

12 So the question is really whether introducing this
13 limit on top of the current exposure limits provides a
14 benefit to the workers that is commensurate with the impact
15 that it could have on the security and career lines of a few
16 and we feel that it does not.

17 Slide six.

18 The principal differences between the EPA guidance
19 and the ICRP 26 recommendations, which are favored by the
20 majority staff view, are that the organ weighting factors
21 are different, and I will come back to that in a moment, and
22 that the non-stochastic organ dose limit is different.

23 The fact is that there is little to choose between
24 these two numbers. The 30 and the 50 both would be
25 effective in avoiding non-stochastic effects. The virtue of

1 the 50 is that it is consistent with the ICRP system which
2 has been internationally accepted and applied.

3 COMMISSIONER AHEARNE: Has it been internationally
4 accepted? The way the paper was written, and I realize that
5 that is now almost two months ago, or it is two months ago
6 in fact, it was that it is in the process of being accepted.

7 MR. ARSENAULT: That is probably a more accurate
8 statement than to say that it has been. The progress is
9 steady and always in the same direction. It seems clear
10 that this is to be the accepted system of dose limitations,
11 but I believe you have more accurately expressed the current
12 situation.

13 With respect to the gonads, the EPA has
14 established a separate organ limit of five rem per year,
15 while the ICRP includes them as one of the organs to be
16 included in the cumulative exposure for the five rem
17 limitation. EPA suggests a 100 rem lifetime limit and the
18 ICRP has no such lifetime limit.

19 COMMISSIONER GILINSKY: Could you say a word about
20 the ICRP? Does it have any official status?

21 MR. ARSENAULT: No, I don't think it has an
22 official status in the sense that I understand the
23 question. We certainly have no commitment to accept the
24 ICRP recommendations.

25 COMMISSIONER GILINSKY: Are countries represented

1 on the ICRP or just individuals chosen or what?

2 MR. ABSENAULT: Individuals are chosen with a view
3 to ensuring international representation.

4 COMMISSIONER AHEARNE: Dick is raising his hand.

5 MR. CUNNINGHAM: The ICRP is mainly a scientific
6 body. Individuals are chosen for their scientific specialty
7 without particular concern for the country from which they
8 are drawn and of course they try to get a balance of
9 viewpoints scientifically. It is typically for their
10 scientific knowledge of their specialty in the area.

11 They don't have an official recognition in the
12 sense that we have or that necessarily their recommendations
13 are adopted by other countries. There is some official
14 tie-in on the books with the first federal radiation policy
15 guidance that came out following the general ICRP
16 recommendations as well as the NCRP. Usually the ICRP
17 recommendations are taken by international organizations.
18 In this case ICRP 26 is taken by IAEA with international
19 labor organizations, the World Health Organization and
20 OECG. They are about to adopt ICRP 26 in their basic safety
21 standards. It is all one document and it is just about to
22 be adopted.

23 COMMISSIONER AHEARN: Is Moeller on that?

24 MR. CUNNINGHAM: Dave Moeller?

25 COMMISSIONER AHEARNE: Yes.

1 MR. CUNNINGHAM: He was on Committee Four. I am
2 not sure if he is still on there now.

3 VOICES: He is.

4 MR. CUNNINGHAM: He is still on there.

5 MR. ARSENAULT: If you will go on to slide seven
6 you will see the difference in the weighting factors that
7 are recommended by EPA and the ICRP.

8 The fact is that except for the difference in the
9 elimination of the separate limitation for gonads provided
10 by EPA and their inclusion as one of the major organs, the
11 difference in these factors is not really significant. I
12 would accept one set of factors over the other as well as
13 the other except that the ICRP does have the virtue of being
14 internationally accepted. Now, this is a more fundamental
15 fact.

16 COMMISSIONER GILINSKY: What problems are created
17 by our not following the ICRP guidelines.

18 MR. ARSENAULT: Because of the way these factors
19 are applied.

20 COMMISSIONER GILINSKY: I don't mean just in using
21 these weighting factors or using any of these
22 recommendations.

23 MR. ARSENAULT: The weighting factors in fact are
24 probably right at the heart of the answer to that question.
25 Using factors other than those recommended by the ICRP

1 actually results in a difference in the definitions of some
2 of the rather basic terms involved because of the way they
3 are applied. This would make it difficult to compare U. S.
4 experience with that of other countries or of anyone else
5 under the different system. It would be possible to make a
6 translation from one to the other but it would awkward.

7 COMMISSIONER GILINSKY: How complicated is this?
8 Are we talking about a little program?

9 MR. ARSENAULT: In some cases it might involve
10 just recalculating everything all the way back to the source
11 data and then calculating forward into the other system.

12 COMMISSIONER GILINSKY: What is it you would be
13 comparing?

14 MR. ARSENAULT: Let's see, rem ---

15 COMMISSIONER GILINSKY: Give me a for instance.

16 MR. ARSENAULT: The end point frequently in the
17 implementation of the system would be to establish derived
18 air concentrations in the case of the ICRP, and I have been
19 warned not to use the word "equivalent," and its comparable
20 term which is a maximum permissible concentration in air for
21 the EPA system.

22 The exposure to these concentrations for some
23 standard work year would be taken as equivalent to five rem
24 exposure. The use of different factors then results in a
25 different level of actual exposure being represented on the

1 records as five rem.

2 If one wanted to do a comparison he would have to
3 back calculate to the actual environment encountered and
4 then apply the other factors and recalculate the exposure.

5 COMMISSIONER GILINSKY: Well, you just come out
6 with a different exposure.

7 MR. ARSENAULT: Yes.

8 COMMISSIONER GILINSKY: But you just do this once
9 as far as I can see.

10 MR. ARSENAULT: You would do any time you wanted
11 to compare the two systems, or you could keep books on both
12 systems so that you could do these comparisons. It is only
13 relevant if you do want to compare your experience.

14 COMMISSIONER GILINSKY: I seem to be missing
15 something here.

16 COMMISSIONER BRADFORD: You have got a lot of
17 volunteers.

18 MR. KREGER: It seems to me important to consider
19 though how we ask for information. The record that we now
20 ask for from licensees, for example, is total external
21 dose. Now, we are in the process of modifying Part 20.
22 But, for example, in that modification we were able to
23 consider that total dose was always obtained in a particular
24 way and the same way that ICRP obtained it, then we wouldn't
25 necessarily have to ask for additional information like how

1 much of that dose is this organ and that organ and how much
2 is internal and how much is external.

3 We could still compare those doses with people
4 that had calculated the total body dose equivalent by the
5 ICRP method if our licensees were doing it by the ICRP
6 method. If we were doing it by a different method you would
7 have to go back and either change the regulation to ask for
8 a lot more information to be able to make the comparison
9 between other countries and other usages or you really
10 wouldn't be able to do it.

11 COMMISSIONER AHEARNE: Are the EPA weighting
12 factors different from the ones that are now in use in this
13 country?

14 MR. ARSENAULT: Are you asking Bill or me?

15 COMMISSIONER AHEARNE: Either.

16 MR. ARSENAULT: Well, we don't use weighting
17 factors in the same way that these are proposed to be used.
18 We have organ limits.

19 COMMISSIONER AHEARNE: I guess what I am getting
20 at is if either the EPA system or the ICRP system is adopted
21 and we now have our licensees reporting doses, so many rems,
22 how are we going to relate that to the information we have
23 up to this time from licensees?

24 MR. ARSENAULT: That is a good question.

25 (Laughter.)

1 CHAIRMAN HENDRIE: There will have to be some
2 factor calculations for conversion.

3 MR. ARSENAULT: With either system.

4 COMMISSIONER AHEARNE: That is what I thought.

5 CHAIRMAN HENDRIE: Bill is waving his hand.

6 MR. CUNNINGHAM: I think the difference is rather
7 simple. ICRP sets their weighting factors so you come out
8 with a comparable risk of five rem.

9 COMMISSIONER AHEARNE: Could you use the mike,
10 Dick. I don't think the people in the back can hear you.

11 MR. CUNNINGHAM: What the ICRP does is take the
12 scientific data by organ does and come out with weighted
13 organ factors that are meant to achieve a comparable risk
14 for the organs comparable to a total body dose of 500
15 milligrams per year or five rem per year. So it is just
16 comparing risk.

17 The EPA, on the other hand, includes in their
18 weighting factors for some organs like the thyroid I
19 thought, but some of them anyway, an ALARA factor, which is
20 an economic factor and this begins to confuse the picture.

21 Now, if you adopt the EPA limits, ALARA changes
22 depending on technology. You aren't comparing risk, you are
23 introducing other factors that destroy that kind of
24 comparison of risk. Now, it is okay to adopt ALARA, but you
25 don't want to do it through this system that just compares

1 risk. Otherwise, it becomes very difficult to go back
2 through the regulations and reconstruct that every time you
3 want to change ALARAs.

4 COMMISSIONER AHEARNE: In other words, Dick, you
5 are saying that it is your impression that the reason that
6 EPA's factors are higher than the ICRP is because they have
7 folded the ALARA concept in.

8 MR. CUNNINGHAM: Yes.

9 COMMISSIONER AHEARNE: Do you agree?

10 MR. ARSENAULT: Well, I must admit that it is not
11 clear to me how they arrived at their factors in detail. In
12 any case, I regard the technical distinction between the two
13 sets of factors as negligible technically.

14 COMMISSIONER AHEARNE: But administratively
15 significant.

16 MR. ARSENAULT: Administratively I think there is
17 a significant difference. We have later in the presentation
18 a qualitative assessment of the cost impacts of these two
19 systems. That is one of the areas in which there would be a
20 significant difference, as I say, because we would be using
21 a system that is fundamentally different from what we expect
22 to be a widely accepted international system.

23 The next slide.

24 Here I have summarized the majority staff
25 recommendations which are that the NRC accept the ICRP 26

1 system with dose limitations for reasons that I think have
2 been made evident now.

3 We feel that they are based on the best scientific
4 data available and have the virtue of being internationally
5 accepted and it would facilitate the sharing of
6 international experience and the comparison of experience.

7 COMMISSIONER GILINSKY: Let me ask you this. What
8 fraction of the total work force that would be subject to
9 either our standards or ICRP standards does the U. S. work
10 force form? In other words, what part of it are we.

11 MR. ARSENAULT: You mean what fraction of the
12 international work force subject to ---

13 COMMISSIONER GILINSKY: Radiation standards.

14 MR. ARSENAULT: I could only guess, and I guess
15 that less than half.

16 COMMISSIONER GILINSKY: Is it about half?

17 MR. ALEXANDER: I don't know what fraction the
18 radiation workers constitute of the world.

19 COMMISSIONER GILINSKY: What fraction of the
20 radiation workers are the U. S. radiation workers?

21 MR. ARSENAULT: What fraction of the worldwide
22 radiation workers subject to systems of this kind does the
23 U. S. radiation work force represent. I think that is the
24 question.

25 COMMISSIONER GILINSKY: Right.

1 MR. ARSENAULT: I am not sure we can get a
2 qualitative answer.

3 CHAIRMAN HENDRIE: If you scale it on power plants
4 it is about a third.

5 MR. ARSENAULT: I think that would be a mistake
6 though.

7 COMMISSIONER AHEARNE: I thought the larger
8 portion of our U. S. workers were not power plant workers.

9 MR. ARSENAULT: That is a question we might have
10 the answer for. Can you give an estimate, Bob, of the
11 fraction of total radiation workers in the U. S. represented
12 by power plant workers roughly?

13 MR. ALEXANDER: Well, there are believed to be
14 more than a million so-called radiation workers in the
15 country now. I guess the power plant workers are now about
16 70,000.

17 MR. ARSENAULT: That is now a large fraction.

18 COMMISSIONER AHEARNE: I am sure, on the other
19 hand, we have probably poor information on the Russian and
20 their country's radiation work force.

21 MR. ARSENAULT: I believe that in the United
22 States the application of nuclear technology outside the
23 power plant industry is perhaps more prevalent than it would
24 be in many countries. My guess would be less than half of
25 the total work radiation workers would be found in the

1 U. S. I won't go beyond that. I would suspect it may be
2 closer to a third.

3 The staff also feels that there should be no
4 career dose limit for reasons that we have discussed at some
5 length. We consider that there are conservatisms involved
6 in the radiation protection systems. There are
7 uncertainties in risk analysis which we feel would make it
8 unreasonable to create the anxiety and the problem for
9 workers, or in the rare cases even a practical problem of
10 security for individual workers on the basis of the proposed
11 benefits that would derived from a career limit.

12 COMMISSIONER AHEARNE: That encompasses then not
13 only disagreeing with the 100 limit of EPA but also dropping
14 the current formula for career limits.

15 MR. ARSENAULT: The current formula for career
16 limits, yes. We feel that that is not necessary.

17 The staff position is also that ALARA issues
18 should be removed from the guidance on occupational dose
19 limitations. The two issues are quite distinct. One sets
20 absolute limits on the exposure which is regarded as safe
21 within the work place. The other principle establishes that
22 one should attempt to achieve some economic balance and to
23 reduce exposures to that which is as low as one can get
24 consistent with the costs and the benefits associated with
25 the activity. They aren't the same and they shouldn't be

1 mixed.

2 Finally, the protection of the unborn should be
3 based on informed consent which is and has been and in our
4 view should continue to be the basis for the NRC approach to
5 this problem.

6 COMMISSIONER AHEARNE: Could you go into that a
7 little bit. I gather you do agree with the minors having a
8 limit of one/tenth the adult workers?

9 MR. ARSENAULT: Yes. Well, one of the advantages
10 in dealing with the minors is that you know what you are
11 dealing with. In the case of fertile women, one of the
12 difficulties is that during a period when the fetus is most
13 sensitive to radiation, neither she nor the employer is
14 likely to know that the condition exists. So that there is
15 some question about the effectiveness of establishing some
16 special protective mechanism.

17 The application of some policy which is uniform
18 with respect to women but not uniform with respect to
19 workers of course raises the problem of a quality and the
20 right to work, et cetera.

21 COMMISSIONER AHEARNE: Let me see if I can ask a
22 couple of questions.

23 Making a limit of one/tenth the adult for minors
24 is based on the conclusion that children are more
25 susceptible?

1 MR. ARSENAULT: Yes. It is based on the
2 sensitivity of the very young and the general policies that
3 relate to child labor laws and protection of minors and the
4 lack of any compelling argument in favor of bringing the
5 minors into the work force.

6 COMMISSIONER AHEARNE: But it starts from the
7 conclusion that the very young are more sensitive?

8 MR. ARSENAULT: It includes that consideration,
9 yes.

10 COMMISSIONER AHEARNE: I tried to read the Bier
11 Report and other material and it wasn't in effect clear to
12 me. Is it correct that the general conclusion is that the
13 fetus is more susceptible? Is that correct?

14 MR. ARSENAULT: Yes, that is a general
15 conclusion. I don't think there is any dispute.

16 COMMISSIONER AHEARNE: So then is it also correct
17 that the reasons of not imposing a limit for pregnant women
18 are based on other than the associated radiation hazard? In
19 other words, what I am saying is that it seems to me that
20 you start with the conclusion of, yes, there is greater
21 radiation hazard there. So that barring other factors you
22 would then, I would conclude, impose a tighter limit because
23 the rest of the rationale, limits at all, limits on minors,
24 seem to have the concept that there is a radiation hazard
25 and when there is a greater radiation hazard you impose a

1 tighter limit.

2 So if the conclusion is that for a pregnant woman
3 there is a greater radiation hazard, in the absence of other
4 factors one would have to impose a tighter limit. It
5 appears that the conclusion that you don't impose a tighter
6 limit has to be based either on it is infeasible or you
7 conclude it is illegal.

8 MR. ARSENAULT: Within the context of your
9 question and within the logic in which it is posed the
10 answer is yes. I would point out to you only that there are
11 some additional considerations that are at least relevant to
12 this.

13 Suppose we found that a particular group within
14 the population at large were more sensitive to radiation
15 than the average among workers, would we then establish a
16 different radiation protection limit for that subpopulation?
17 I don't know the answer to that.

18 COMMISSIONER AHEARNE: Well, we already have. It
19 is called minors.

20 MR. ARSENAULT: I am just pointing out that while
21 I would be prepared to answer the question you asked in the
22 affirmative as a personal view, and I think it is widely
23 shared, it could not be extended to apply to other
24 populations necessarily.

25 COMMISSIONER AHEARNE: That is not obvious. What

1 I am trying to understand is the regulatory philosophy that
2 underlies the conclusion and then, if I understand that
3 correctly, I have to conclude that there are other factors
4 which take you away from that. I just wanted to make sure I
5 understood what those other factors were.

6 MR. ARSENAULT: That is correct. As I said, I
7 would answer the question that at least internally I would
8 answer in the affirmative. There is a recognized higher
9 level of risk per exposure.

10 COMMISSIONER AHEARNE: That is why the ICRP then
11 came up, at least according to your table, they have reached
12 a conclusion that there should be a tighter restriction
13 imposed on pregnant women.

14 MR. ARSENAULT: Yes, on pregnant women, right, and
15 it is a part of the consideration that goes into the lower
16 limit.

17 Slide nine goes to the point which I indicated a
18 moment ago. It is at the heart of the difference between
19 the two systems and deals with the radioactivity intake
20 factors, the annual limits of intake.

21 It should be recognized that the ICRP system is
22 generally more restrictive than current standards. The same
23 could be said of the EPS system.

24 COMMISSIONER GILINSKY: Could you give us some
25 indication of the degree to which current standards would

1 have been tightened?

2 MR. ARSENAULT: Would be tightened?

3 COMMISSIONER GILINSKY: Yes.

4 MR. ARSENAULT: Well, it is difficult to be
5 quantitative, but it goes back to the argument I mentioned
6 on the very first slide. When one applies the same five rem
7 annual limitation but not computes the exposure as a result
8 of both external and internal dose, there is almost
9 inevitably a reduction in the allowed exposure as a result.
10 As I say, it is a little difficult to translate that
11 quantitatively because the systems are so different.

12 COMMISSIONER AHEARNE: Is it true that the
13 concentration factors though are relaxed?

14 MR. ARSENAULT: No. In general I think they will
15 not be relaxed. The next point on this slide is that some
16 of the derived air concentrations would be higher than the
17 current maximum permissible concentrations. That is, some
18 would be relaxed. Therein lies one of the points in the
19 EPS's system.

20 COMMISSIONER GILINSKY: Could you explain why that
21 is?

22 MR. ARSENAULT: Yes. I can explain in general
23 terms, but if you push me beyond the superficial I am going
24 to have to get help.

25 (Laughter.)

1 The application of the current limitations on all
2 organs results in derived air concentration limits that are
3 based on the metabolic relationship between the exposure of
4 the individual to that air concentration and the consequent
5 deposition and exposure to a specific organ.

6 When one moves to either the EPA or the ICRP
7 standard in which the risk to the individual resulting from
8 organ dose is considered, then the organ dose may very well
9 be increased or decreased compared to the current
10 standards. Even if one used the same metabolic models, then
11 the derived air concentration would be increased in the case
12 where the organ to which that radionuclide was most relevant
13 had its dose increased by this risk approach. So in some
14 cases they might be increased.

15 In addition, new metabolic models are being
16 applied which could have the effect of increasing the air
17 concentrations even when the organ doses were the same. So
18 both factors can work to result in increased permissible air
19 concentrations of specific radionuclides, and in some cases
20 that is the result of the application of this new system.

21 COMMISSIONER GILINSKY: How great an increase are
22 we talking about?

23 MR. ARSENAULT: I don't know the figures on that.
24 Has anyone done calculations?

25 MR. ALEXANDER: They range from about 10 percent

1 to a factor of 17 in the case of Strontium 90.

2 MR. SHLOMO: I have here a whole listing of
3 available comparison figures. It shows some lower and some
4 higher.

5 COMMISSIONER AHEARNE: Is the strontium the
6 highest?

7 MR. SHLOMO: Strontium 90 is insoluble. In 10 CFR
8 20, strontium is two times ten to the minus nine, that is your
9 lowest. The soluble is eight times higher and this comes
out to a calculation equivalent to this.

10 COMMISSIONER AHEARNE: Now, is the difference
11 between the EPA and the ICRP based on EPA's disagreement
12 with the technical basis or based on the belief that you
13 should not raise a limit that is already existing?

14 MR. SHLOMO: First of all, there will be a
15 difference between the ICRP and EPA based on the different
16 weighting factors and based on the difference of the cap
17 30 rem versus 50 rem ICRP.

18 In addition, EPA made the recommendation that for
19 those cases where the new derived limits turn out to be
20 higher than the one in current use the old one should be
21 retained. We consider this being an issue of ALARA. Those
22 limits, as Mr. Arsenaault explained, were derived in a
23 coherent system based on the same risk. We have better
24 models, we have better understanding of carcinogenicity of
25 the different organs and they might result in different

1 limits.

2 If you would arbitrarily change those limits, then the
3 relative concentration of the annual limits of one radionuclide
4 versus another radionuclide will lose the equivalence of risk and
5 it will cause considerable problems in our reviewing summation.

6 Whenever from an ALARA standpoint it is feasible
7 and desirable to lower the limits, then our regulation or
8 guidance might say this particular licensee would want half
9 the limit, but let not change the limits.

10 MR. ARSENAULT: This discussion in fact moved us
11 well down this list. The comments you just heard explain
12 why the DACs and MPCs, that is the derived air concentration
13 limits in the ICRP system and the maximum permissible
14 concentrations in the air in the EPA system, are not
15 directly comparable.

16 Also, Dr. Yaniv has addressed the question of the
17 fact that the DACs are based on contemporary scientific data
18 and equivalency of risk so that when the sensitivity of
19 individual organs is taken into account, as we indicated,
20 the derived air concentrations may in fact be larger than
21 they are under the current system of organ limits.

22 Dr. Yaniv also addressed the fifth item. He is
23 making my life very easy, and that is that the majority
24 staff view is that when these derived limits turn out to be
25 higher, taking into account the various factors that are
26 relevant to this equivalent risk calculation, then one

1 should establish these limits at that derived value.

2 The control at lower limits of exposure is, as he
3 pointed out, an ALARA issue and we feel that in many cases
4 it will be justified to apply lower limits but through the
5 application of ALARA rather than the equivalency of risk
6 principle.

7 Slide ten.

8 The question of the implementability, the
9 convenience or complexity of implementing the ICRP 26 system
10 has been discussed. This of course will be decided entirely
11 within the context of the regulations that are drafted to
12 implement this system.

13 We are looking at the revisions implied for 10
14 C.F.R Part 20 now and it is our goal to establish for
15 licensees that have specific exposure conditions simplified
16 means for summing the internal and external exposures. For
17 the other licensees in which such simplification is not
18 possible, we expect to provide specific procedures and
19 guidance on how to go about performing that.

20 COMMISSIONER AHEARNE: What is the status of the
21 revision of Part 20?

22 MR. ARSENAULT: We have in hand a draft of the
23 rule itself. It now remains for us to document the
24 considerations that went into that draft in the statement of
25 considerations as supplementary information. That is

1 underway and it is probably some weeks away from being ready.

2 Also, the rule is drafted as a rule and therefore
3 it implies various things to the licensee rather than
4 specifying them and we need to document some of those
5 implications.

6 COMMISSIONER AHEARNE: To the extent that it is a
7 germane question, does it track more to EPA recommendations
8 or the ICRP 26 recommendations?

9 MR. ARSENAULT: It tracks the ICRP 26
10 recommendations.

11 Another point which is common to
12 the various systems that are being considered, it is common
13 to EPA and ICRP and it is common also to the current 10
14 C.F.R. Part 20, is that the 50-year committed dose from the
15 intake of radionuclides in any particular year is taken into
16 account that year. In other words, the 50-year commitment
17 is put on the records in the year in which the radionuclide
18 is absorbed.

19 There has been some discussion with those not
20 subject to 10 C.F.R. Part 20 that this would be an extremely
21 difficult or awkward requirement to fulfill. We would only
22 make the observation that there isn't any change from the
23 existing system of regulations in this respect.

24 With regard to costs, we felt that we should
25 address this, but it is extremely difficult to assess what

1 the cost implications are for any of these systems until
2 they have been translated into practical regulations. But
3 we have done our best to try to indicate whether we would
4 expect the costs to be either minor or significant.

5 In the case of the justification requirement, we
6 feel this would be minor. We feel that justification is
7 required by current procedure but it would have to be made
8 more explicit under the new systems.

9 The requirement that ALARA be made mandatory
10 implies that the licensees will have to be more rigorous and
11 explicit in documenting the rationale for and the
12 application of the ALARA principle and that NRC will of
13 course have to review and approve these and that there will
14 be some enforcement applications as well. So we would rank
15 the cost implications at this point as significant.

16 The system of dose limitations and the application
17 of these calculational methods, in either system the initial
18 cost would be significant. We feel that the EPA guidance,
19 because it would require these complex translational
20 manipulations in the future, has the potential for a much
21 more significant ongoing cost than the ICRP approach.

22 COMMISSIONER AHEARNE: If one wants to do that
23 translation.

24 MR. ARSENAULT: Yes, if one wanted to do the
25 translation. I think it is clear that we would want to

1 benefit from the experience of radiation exposure in other
2 countries and to compare our experience with theirs. A
3 great deal can be learned from that. My own view is that
4 such a translation is inevitable.

5 With regard to the radiation protection
6 requirements, that is the required ---

7 COMMISSIONER AHEARNE: Before you lose that point
8 let me ask you a question. The radiation exposure history
9 of the bulk of the people in the United States who are
10 exposed to radiation is maintained under whose regulation?
11 Is it NRC or is it non-NRC? The EPA guidance would apply to
12 some class of people.

13 MR. ARSENAULT: Yes.

14 *Commissioner Ahearn:*
~~MR. ARSENAULT:~~ How large a segment of that are
15 the people that we regulate?

16 MR. ALEXANDER: The percentage of workers affected
17 that the NRC regulates is 15 percent.

18 COMMISSIONER AHEARNE: Of all of those who would
19 be affected by the EPA guidance?

20 MR. ALEXANDER: Yes.

21 COMMISSIONER AHEARNE: So most of the people to be
22 affected by the EPA guidance are not regulated by the NRC?

23 MR. ALEXANDER: Yes. When I say 15 percent I am
24 talking about the I believe 26 non-agreement states where we
25 license and regulate the rest. I don't know what the number

1 is.

2 COMMISSIONER GILINSKY: Where are most of the rest
3 of the workers? In what sort of industry?

4 VOICE: Medical, X-ray.

5 COMMISSIONER GILINSKY: Is that where the bulk of
6 it is?

7 MR. ONG: The EPA background documents out in 1975
8 were 1,160,000 U. S. workers. The number I got from John
9 Davis about three days ago was workers covered by NRC
10 totalled 233,000 right now of which there was 78,000 ---

11 COMMISSIONER AHEARNE: But you would have to fold
12 in the agreement states on top of that.

13 MR. ONG: I would say about 25 percent of the
14 total workers.

15 CHAIRMAN HENDRIE: What happens to the records of
16 workers licensed in agreement states in activities that we
17 would license if they were not agreement states? Do we end
18 up holding those records or do the states or who?

19 MR. ALEXANDER: They are held by the licensees.

20 CHAIRMAN HENDRIE: By the licensees.

21 COMMISSIONER AHEARNE: The ideal situation is the
22 world and the rest of the U. S. all use the same system and
23 then you don't have to translate. But if there is going to
24 be a disagreement, it is not clear to me whether we would be
25 more concerned with comparability with the rest of the world

1 or more concerned with comparability with the rest of the
2 U. S.

3 MR. ARSENAULT: The EPA standard would apply to
4 those who are regulated by the NRC.

5 COMMISSIONER AHEARNE: I understand that. But you
6 see, the EPA is committed and goes down one path and we go
7 down the ICRP path. It wasn't clear to me that we would be
8 better off in the ones we had to do our comparison with.

9 MR. ARSENAULT: Well, I think I should point out
10 that while the staff majority strongly favors the ICRP
11 approach over the EPA approach, and we are recommending to
12 the Commission that the NRC officially inform EPA of this
13 preference, it seems clear that whichever direction EPA
14 ultimately decides that the NRC is likely to fall in line
15 behind it. That is precisely why we feel that now is the
16 time to convey to the EPA what our current perceptions are.

17 COMMISSIONER AHEARNE: We don't have to though, do
18 we?

19 MR. ARSENAULT: I would turn to my legal counsel.

20 MS. BECKER: If you will notice on page 3 of the
21 staff paper in a footnote OELD has rendered the opinion that
22 although we are not compelled to follow EPA guidance, as a
23 matter historically and as a matter of fact we probably
24 would. Mrs. Mapes who wrote the legal opinion on that is in
25 the audience.

1 COMMISSIONER AHEARNE: Not with EPA?

2 MS. BECKER: No, here.

3 MR. ARSENAULT: So that implication is in our
4 minds.

5 CHAIRMAN HENDRIE: Let's hear what Bill has got to
6 say and then we will get to Jim.

7 MR. KREGER: Well, I think Frank started out by
8 saying that there is practically universal disagreement with
9 the EPA guidance. Every one of the actual rules that gets
10 established that implements that guidance will be done by a
11 particular agency like NRC or the Department of Energy or
12 the Department of Defense and so forth.

13 If all of them disagree with it, the question of
14 whether any or very many will actually implement those as
15 they now stand is quite in doubt I think.

16 MR. TRUBATCH: I think we have to distinguish
17 between an independent regulatory agency and an Executive
18 Branch agency as far as compliance with the FRC standards.

19 MR. ARSENAULT: It is clear to EPA that a very
20 significant revision of their standard is implied by the
21 results of the hearings. What direction they will go in is
22 of course a matter of speculation.

23 CHAIRMAN HENDRIE: Do you still have a comment you
24 wanted to make?

25 MR. CUNNINGHAM: Just on the question that

1 Commissioner Ahearne raised of whether we wanted to compare
2 internationally our results under standards or nationally.
3 The issue goes much more beyond that. It is whether or not
4 we are able to maintain orderly and systematic regulations
5 that we can review on a periodic basis.

6 If we follow the EPA method we have ALARA built
7 into the basic limits where we are really dealing with a
8 risk number. As time goes on that becomes extremely
9 confused. When ALARA changes it means we have got to change
10 our basic radiation protection limits and that is not the
11 way the system should operate because we will have a series
12 of ALARA numbers depending on what industry we are
13 regulating. It just becomes chaotic if you follow the EPA
14 system over the long term.

15 COMMISSIONER AHEARNE: I had been told, and I
16 guess Bob since he attended all the hearings can verify or
17 contradict. I have been told that in the hearings there
18 were comments made that some of the foreign governments are
19 having difficulty following the ICRP 26 recommendations,
20 either understanding them or implementing them.

21 MR. ALEXANDER: That is true.

22 COMMISSIONER AHEARNE: Was that because they found
23 them difficult or found them sufficiently confusing and
24 illogical?

25 MR. ALEXANDER: I am sorry. Right now I don't

1 have the details.

2 MR. CUNNINGHAM: I might add to that that I tended
3 leaning to translate the ICRP 26 recommendations into the
4 international basic radiation protection standards for these
5 various international organizations.

6 It is true that a lot of countries have trouble
7 translating ICEP into a practical working regulation. The
8 international standards are sort of an intermediate thing.
9 Our people in developing Part 20 have a difficult time but
10 it can be done.

11 The system is set out in ICRP. Everybody I have
12 talked to from other countries seemed to agree that the
13 system is good, but it takes a lot of work and a lot of
14 experience getting to the practical applications down at the
15 level where you are working in the field and where working
16 health physicists can utilize them easily but that is our
17 responsibility. It is workable and I haven't heard anything
18 to the contrary.

19 MR. ARSENAULT: On radiation protection
20 requirements, the EPA guidance, as I mentioned earlier,
21 includes a requirement that a three-tier system be
22 established and prescribes the radiation protection
23 requirements at each level. We feel that will impose a
24 significant administrative burden on the licensee with
25 consequent costs on it, and that the application through

1 regulations of reference levels and appropriate general
2 guidance for each is a more effective way of achieving a
3 similar result. That could be done through the application
4 of the ICRP recommendations.

5 The EPA requirement that the lower of either
6 current or new derived limits be applied we feel would
7 represent a significant cost for reasons that have been made
8 clear. Mr. Cunningham referred to this. This confuses
9 ALARA issues and radiation protection limits issues and will
10 result in additional difficulty in trying to compare the
11 dose records for individual workers.

12 Limits lower than the radiation protection guides
13 for specific jobs. There is a recommendation that
14 regulatory agencies for specific activities establish limits
15 lower than those prescribed in the radiation protection
16 guides. This would, in our view, create regulatory
17 confusion that we feel would be better avoided and
18 represents costs both for the agencies and for the licensees.

19 With regard to the issues on minors, there are no
20 cost impacts from either system.

21 With regard to the unborn, the question marks
22 merely indicate that the EPA did not take a specific
23 position on that.

24 The provisions for exceeding the radiation
25 protection guides under specific circumstances don't have

1 significant cost impact in either system.

2 Finally we get to the Hiroshima and Nagasaki
3 data. The question was asked earlier whether the staff
4 position reflects the new dose calculations for Hiroshima
5 and Nagasaki. The answer is no.

6 In fact, the point we would make rather
7 emphatically is that the current discussion on this issue is
8 fraught with uncertainties. There seem to be no bases for
9 arriving at firm conclusions in either direction. The data
10 is very preliminary. Each discussion of the issues involved
11 in these recalculations identify new parameters, the
12 sensitivities to which you have ---

13 COMMISSIONER GILINSKY: Well, wouldn't there be a
14 change if you accepted the new results as being correct?

15 MR. ARSENAULT: Well, the problem is that there is
16 no coherent set of results that one can accept as correct
17 and apply to effect changes. I will, however, answer your
18 question by saying that the best staff estimates are that
19 the largest likely impact on the radiation protection guides
20 might involve a factor of two and possibly three. It is in
21 that range.

22 COMMISSIONER GILINSKY: Translating into a factor
23 of two or three in air concentrations or what?

24 MR. ARSENAULT: Potentially, yes.

25 MR. SHLOMO: Not necessarily higher but it could

1 be also lower.

2 MR. ARSENAULT: Yes. There is no clear indication
3 of which way this will go.

4 COMMISSIONER GILINSKY: Why would it be lower? I
5 thought the new data suggested that the effects ---

6 MR. SHLOMO: The total dose in Hiroshima was
7 higher based on the new calculation, but lower. Not lower,
8 it was only the neutron component that was lower.

9 COMMISSIONER GILINSKY: Right. Given certain
10 effects that suggests that the ---

11 MR. ARSENAULT: The risk is lower.

12 MR. SHLOMO: The risk is lower. If you have a
13 higher does it has the same effect.

14 MR. ARSENAULT: The risk would be lower and the
15 effect on the regulations would be to relieve them.

16 MR. SHLOMO: It is a question between neutron and
17 and gamma. It is not a simple drop in our direction. There is
18 an analysis that shows for certain types of tumors there are
19 slight increases and for total tumors it decreases based on the
20 new dose system and the data. This is a paper from Lawrence
21 Livermore by Strom and Dobson.

22 COMMISSIONER GILINSKY: Were they saying that the
23 gamma dose was higher or were they saying that there was no
24 neutron dose?

25 MR. SHLOMO: The original paper by Lowell and
26 Mendelson which wasn't published is a preprint based on the
27 table of a comparison of the T-65 doses and the recalculated

1 doses. On a rad basis, there are curves in here, on a rad
2 basis the total dose in Hiroshima comes out to be higher.
3 The gamma component is higher. The neutron component is
4 lower. In Nagasaki the neutron doses are lower. Most of
5 the health effects come from Hiroshima.

6 MR. ARSENAULT: I hasten to point out that most of
7 this data represents preliminary results. Little of it has
8 been subjected to publication in referee journals and the
9 usual scientific debate and peer review that we would like
10 to see before accepting it as valid. The staff position is
11 succinctly stated that there simply is no basis for deriving
12 firm conclusions from the available information and that it
13 could go in either direction.

14 COMMISSIONER AHEARNE: Frank, was there a meeting
15 in May?

16 MR. ARSENAULT: Yes, there was.

17 COMMISSIONER AHEARNE: Did anything concrete come
18 out of that meeting?

19 MR. ARSENAULT: Only a concrete recognition of
20 chaos. I think that is a fair statement.

21 COMMISSIONER AHEARNE: In the Science article that
22 was one of the few published areas on it essentially a
23 reader would reach the conclusion that the NRC was
24 uninterested in trying to explore this area.

25 MR. ARSENAULT: One can infer that from the

1 article. I did not.

2 COMMISSIONER AHEARNE: I am not saying it would be
3 correct. I wanted to lead to the question are we interested?

4 MR. ARSENAULT: I think the answer is that we are
5 keenly interested in the debate itself and the results of
6 it. I point out, however, that the current staff view is
7 that it will not have a very large impact on our regulations.

8 COMMISSIONER AHEARNE: I was just concerned. This
9 sounded as though even the exploration of the issue couldn't
10 get funded anywhere. The one agency that was willing to
11 fund it and the guy says that well, it really isn't our area
12 of interest but nobody else would pick it up.

13 MR. ARSENAULT: I understand your question a
14 little more clearly now. I think that if we could see an
15 avenue of supporting research which would resolve some of
16 the issues we would be happy to support it within the limits
17 that are available to us.

18 I do believe that the implications of this are so
19 far reaching and so broad and so universally applicable that
20 it seems far more fitting ---

21 COMMISSIONER GILINSKY: This is what now?

22 MR. ARSENAULT: This is the resolution of some of
23 the questions that are involved in the recalculation of the
24 Hiroshima and Nagasaki doses.

25 The implications are so broad in their application

1 that we consider it far more fitting that one of the
2 agencies doing the basic research in this area does support
3 it. Now, I would not reject a proposal that the NRC ---

4 COMMISSIONER AHEARNE: I guess my concern would
5 only be that I would hope the work gets done and doesn't get
6 put aside because every agency feels that it is so board
7 that it clearly is not their responsibility to do it.

8 MR. ARSENAULT: Well, I am not aware there is any
9 danger of that at this point.

10 COMMISSIONER GILINSKY: Let's see. Does what you
11 are saying now jibe with what you were saying earlier? Now
12 you seem to be saying that this may have a pretty major
13 effect on all the conclusions.

14 MR. ARSENAULT: The breadth of its effect should
15 not be confused with its magnitude.

16 (Laughter.)

17 COMMISSIONER GILINSKY: Come again?

18 MR. ARSENAULT: Well, when I say it has far
19 reaching implications I think it has implications for
20 policies for the use of radiation in various agencies. It
21 has a potential impact on the dose calculation in many areas
22 not regulated by NRC. It is that sense of breadth is what I
23 meant.

24 COMMISSIONER GILINSKY: What led you to recommend
25 different numbers for the various regulatory limits? That

1 is what I am asking. Does it have that potential?

2 MR. ARSENAULT: Yes. I have made the point that
3 the best staff estimate now of the impact that it might have
4 on health risks associated with radiation exposure are
5 within the factor of two or three. Given the uncertainties
6 associated with the dose effect relationships right now I do
7 not regard those as large factors. We certainly would
8 reflect them in our regulation.

9 I want to point out before leaving that point that
10 the current regulatory standards are based on what we regard
11 as a conservative reliance on the no-threshold linear dose
12 relationship. If one accepts the lightly linear quadratic
13 dose effect relationship that is implied by the data, there
14 is a conservatism built in. The risk estimates now are
15 based not only on Japanese data, so that one must be guarded
16 in assessing the impact they should have. So the best staff
17 estimates are for a factor of two to three. I should
18 perhaps say the maximum.

19 COMMISSIONER GILINSKY: Do we have any work going
20 on in this area at all? Is anybody looking at it in NRC?

21 MR. ARSENAULT: Well, again, in the sense of the
22 Hiroshima and Nagasaki data, no. Everyone in the NRC is
23 looking at it right now but we are not funding any work
24 which is aimed at resolving the issues raised.

25 COMMISSIONER GILINSKY: Is anybody doing any work

1 in house other than reading these articles?

2 MR. ARSENAULT: Other than reading the results of
3 the research that is going on, I would say no.

4 COMMISSIONER AHEARNE: What about that Chicago
5 meeting.

6 MR. ARSENAULT: In fact, we received reports from
7 the Chicago meeting. We did not send a staff member, no.

8 COMMISSIONER GILINSKY: Why don't we do something?

9 MR. ARSENAULT: You mean why are we not funding
10 research?

11 COMMISSIONER GILINSKY: Or do some calculations on
12 our own.

13 MR. ARSENAULT: We are doing calculations. We are
14 following the results of the research in the scientific work
15 carefully.

16 COMMISSIONER AHEARNE: Of course, the basic
17 calculations aren't really things that we would be able to
18 do. The basic calculations are recalculation of the actual
19 doses in Nagasaki and Hiroshima.

20 COMMISSIONER GILINSKY: Well, he can look and see
21 whether he agrees with them or not.

22 COMMISSIONER AHEARNE: I am a little disturbed we
23 didn't even go to that meeting.

24 MR. ARSENAULT: Well, it was a judgment call on a
25 last-minute basis and we assessed the risk. We felt that we

1 were adequately represented by people whose judgment and
2 reporting capability we trusted.

3 MR. ALEXANDER: Well, I think the scientific
4 community right now is trying to decide how to approach this
5 problem, particularly through the NCRP. Once those
6 decisions are made, I am sure we can be looking for some
7 visits for funding.

8 COMMISSIONER AHEARNE: Should we reflect at least
9 some of this in our comments to EPA?

10 MR. ARSENAULT: Someone asked me that question
11 yesterday and I puzzled over how we might reflect our
12 perception of the current debate in our comments to EPA and
13 concluded there wasn't anything useful we could say.

14 COMMISSIONER AHEARNE: Well, I guess at a minimum
15 we might reach a conclusion that here is a major issue that
16 seems to be growing in this particular area. Silence
17 indicates either we don't know of it or we don't believe
18 that EPA should do anything about it.

19 We could either say we know of the issue and we
20 don't see it being able to be resolved in the near future so
21 EPA should go ahead, or we could say we know of the issue
22 and we don't think it is going to be able to be resolved in
23 the near future but we think EPA ought to at least hold
24 until a further assessment is done.

25 MR. ARSENAULT: Yes.

1 COMMISSIONER AHEARNE: We could do one of those
2 which would be a more positive position on our part as to
3 what EPA ought to do with respect to this.

4 MR. ARSENAULT: I think a statement that we
5 believe that we should continue to make efforts to take
6 account of the best available information while the work is
7 going on to resolve some of these issues would be possible
8 and possibly useful.

9 COMMISSIONER AHEARNE: Do you think EPA ought to
10 hold until that is resolved?

11 MR. ARSENAULT: No, I do not.

12 COMMISSIONER AHEARNE: I would guess we ought to
13 say that if that is where the consensus is.

14 MR. ARSENAULT: My understanding of their views
15 perhaps prevented me from focusing on the utility of that
16 observation. We can include that.

17 I believe that brings me to the end of the
18 prepared presentation.

19 CHAIRMAN HENDRIE: Other questions?

20 COMMISSIONER AHEARNE: I would like to I guess
21 before getting to the minority views at least understand.
22 As I read your chart and read the minority views, at least
23 one of them, the minority believed that there should be a
24 notification system set up for high dose workers when a risk
25 reaches some preset level. I gather the staff majority does

1 not agree with that. Could you explain what would be wrong
2 with that?

3 MR. ARSENAULT: Yes. Perhaps I should briefly
4 summarize the minority views and the staff's reaction to it.

5 In the minority view No. 1, as it is referred to
6 here, which is that of Dr. Alexander, and he can address it
7 at greater length, there are two points.

8 The first is that the lower of either the current
9 or new derived limits be applied and we have already
10 addressed that in relation to the EPA standard.

11 The second is that rather than having a lifetime
12 dose limit that some pre-established risk be used as a point
13 at which the worker would be informed.

14 The current work on the revision to 10 C.F.R. 20
15 includes within it consideration of the mechanisms for
16 informing workers on a more routine basis as to the levels
17 of exposure and of keeping workers informed concerning the
18 implications of that exposure.

19 The identification of some specific level of
20 exposure is likely to imply that that level has some
21 property about it that other levels do not have and of
22 course this would not be true.

23 COMMISSIONER GILINSKY: But that is true of every
24 level.

25 MR. ARSENAULT: Exactly.

1 COMMISSIONER GILINSKY: Somewhere you have got to
2 set requirements and points at which you become concerned.
3 You know, there is a certain arbitrariness about them, but
4 you know it is just like day and night. It is hard to tell
5 when day goes into night but there is a difference between
6 noon and midnight.

7 MR. ARSENAULT: That is true.

8 COMMISSIONER GILINSKY: This is pretty readily
9 apparent.

10 MR. ARSENAULT: That is true. The alternative,
11 however, that we have offered that we are considering is not
12 to use that argument to not notify at any level but rather
13 using that argument to indicate that he should be notified
14 at every level. The question of a routine notification and
15 a general worker education program is the alternative to
16 notifying ---

17 COMMISSIONER GILINSKY: What is the concern here,
18 that the worker will be unnecessarily upset or what?

19 MR. ARSENAULT: Well, there is the question of
20 whether some specific level should be identified for worker
21 notification.

22 COMMISSIONER GILINSKY: Would you see some effect
23 on his job as a result of him crossing a point which is, you
24 know, while it is not a regulatory limit would nevertheless
25 be some sort of a threshold?

1 MR. ARSENAULT: Some of the staff have raised as
2 one of the points to be considered the impact on the
3 employer's practices of establishing this notification
4 level, that it might affect practices in a way that is not
5 consistent with its intention and might regard it as some
6 non-official limit and try to avoid reaching levels at which
7 the level were notified.

8 COMMISSIONER GILINSKY: That isn't so bad, is it?

9 MR. ARSENAULT: Well, it depends a little bit on
10 the means that the employer uses for not reaching that level.

11 COMMISSIONER GILINSKY: What are you saying?

12 CHAIRMAN HENDRIE: If you fire a guy who is five
13 percent below the level, why that may not be to the worker
14 force a satisfactory way of observing the limit.

15 COMMISSIONER GILINSKY: Is that what you mean?

16 MR. ARSENAULT: That is one of the possible ways
17 he might arrive at it. He might apply some techniques for
18 using more people for particular activities to limit
19 exposure. He may accept this notification limit as an
20 unofficial limitation on exposure. As such it would replace
21 the authoritative limits on exposure.

22 Now, that has a number of implications, one of
23 which Chairman Hendrie mentioned. The other is the way he
24 might apply these techniques. It is only an element that
25 has been raised. It is not a compelling argument.

1 COMMISSIONER GILINSKY: What is the opposite side
2 of this discussion?

3 MR. ARSENAULT: The argument in favor?

4 COMMISSIONER GILINSKY: Yes.

5 MR. ARSENAULT: I would suggest that Dr. Alexander
6 might want to offer that himself, if we could ask him to
7 comment.

8 MR. ALEXANDER: Well, I have never been a staff
9 minority before so I don't know exactly how to handle this
10 except just to relate to you what my thinking is.

11 I think the issue that we are dealing with is
12 whether or not the government should be concerned about a
13 small group of high dose workers that are in a higher risk
14 category than other radiation workers. We don't know
15 exactly how many there are but it is almost certainly less
16 than a thousand and may be as few as only four or five
17 hundred workers who get five rems per year every year or
18 more.

19 So that out of maybe a million and a half
20 radiation workers how concerned should we be about this
21 small group?

22 COMMISSIONER GILINSKY: Let me ask you, would you
23 expect those to be concentrated in one or another industry,
24 or would they be spread around?

25 MR. ALEXANDER: No. They are concentrated

1 primarily in the nuclear power industry and in the medical
2 industry.

3 (Laughter.)

4 COMMISSIONER GILINSKY: That is about right.

5 (Laughter.)

6 MR. ALEXANDER: That was a Freudian slip, I am
7 afraid.

8 (Laughter.)

9 If we don't need to be concerned about so few
10 workers then the problem goes away of whether the government
11 should do anything about it or not and I believe that pretty
12 much represents the staff majority opinion.

13 The EPA feels that something should be done about
14 them and I agree with the EPA. The only thing is I don't
15 agree that a career lifetime limit is the proper way to go
16 because of potential career interference by the government
17 and I believe there are other ways to go about it.

18 If I might use an analogy. If a worker who had
19 been receiving five rems per year for ten years decided to
20 leave the nuclear industry and become a test pilot, I
21 believe we would all agree that the government should not
22 interfere with him in choosing that new career. I believe
23 that the same thing applies if he wants to continue after
24 getting any dose levels, such as a hundred rem, if he wants
25 to continue being a power worker, the Federal Government

1 shouldn't tell him that he can no longer do that.

2 But I do believe that we ought to do something.
3 What I think we should do is simply make sure that these
4 workers understand that they are in a higher risk category.
5 That brings up the idea of the risk notification system so
6 that when a worker arrives at a level of risk comparable
7 with other safer industries that he be notified that he has,
8 according to the best scientific estimates that have been
9 developed, that he has arrived at that point and now is the
10 time for him to make an informed decision as to whether or
11 not he wants to continue in radiation work.

12 COMMISSIONER AHEARNE: Let me ask just a couple of
13 other questions.

14 With respect to No. 9, you have on the chart that
15 you sent up that the majority agrees with ICRP 26 which
16 sounds like on your chart a very explicit set of limits. I
17 thought from reading 81-232 that this majority opinion on
18 the No. 9 was a general description. So which was correct?

19 MR. ARSENAULT: I am not sure that I understood
20 the question.

21 COMMISSIONER AHEARNE: If I turn in here to your
22 answer, the letter that you are proposing to send in
23 recommendation No. 9, it says that you would like to revise
24 the existing recommendation and you have some language
25 revising it. It essentially says that the licensee can

1 exceed the RPGs for cause and the agency can establish on a
2 generic basis the reasons for doing that.

3 On the chart you have sent up it says the ICRP
4 recommendation is the one that you endorse and the ICRP
5 recommendation is that you can exceed the RPG to twice the
6 annual limit per event at five times this limit in a
7 lifetime. Those just don't seem to be the same.

8 MR. SHLOMO: You are basically correct. There is
9 a discrepancy in the Commission paper. There is no mention
10 of specific limit. In the staff discussion in the
11 preparation of the Commission paper we agreed that the
12 limits as represented ICRP 26 or exceeding RPG would be the
13 appropriate one. Therefore, maybe not entirely correctly,
14 it appeared on this majority staff position.

15 COMMISSIONER AHEARNE: Does that mean that you
16 would propose to revise the response to EPA or does it mean
17 that you would propose that if EPA accepted your proposal
18 that the way that we would implement it would be to ---

19 MR. SHLOMO: The second.

20 COMMISSIONER AHEARNE: I see. All right. I guess
21 I would agree with that as being a better approach, but I
22 just wanted to make sure I understood.

23 You also say in your chart that we, as far as No.
24 2 on ALARA, we would accept ICRP 26. Now, ICRP 26 includes
25 the concept of optimization. That is what you would want

1 EPA to include in their proposed rule or in their rule; is
2 that correct?

3 MR. ARSENAULT: The difference is EPA optimizes on
4 the collective dose and we are not sure that that specific
5 parameter should be the one that optimizes over.

6 COMMISSIONER AHEARNE: I didn't recall EPA
7 introducing the optimization concept.

8 MR. ARSENAULT: Well, they didn't refer to
9 optimization. They simply say that ALARA should be applied
10 to reduce the collective dose to levels as low as reasonable.

11 COMMISSIONER AHEARNE: Right.

12 MR. ARSENAULT: That is a specific parameter.

13 COMMISSIONER AHEARNE: I thought optimization
14 brought the cost aspect in much more strongly. Is that
15 incorrect?

16 MR. ARSENAULT: I suppose it is a matter of the
17 way you read it. It is the words "as low as reasonably
18 achievable" that brings the cost impact to bear.

19 COMMISSIONER AHEARNE: So when you say that you
20 would endorse the ICRP approach you would like to remove the
21 collective aspect? I gather you are drawing a distinction
22 between the EPA approach and the ICRP approach and I am
23 trying to understand what that distinction is that you are
24 drawing.

25 MR. ARSENAULT: I would like to find the exact

1 words. If I can ask my associates to pitch in on any point
2 on which I go awry.

3 (Laughter.)

4 I think the distinction is that in arriving at an
5 optimization one looks at a larger number of factors related
6 to the dose reduction as opposed to the cost of achieving
7 that reduction than merely collective dose which is a
8 specific parameter in the EPA standard. To us that is a
9 preferable way of expressing what our goals are.

10 MR. ALEXANDER: I worked with the EPA people in
11 developing this guidance for a period on the order of six
12 years and I think I understand what they are after with
13 respect to the ALARA concept. They want the ALARA concept,
14 the occupational ALARA concept to be implemented by all the
15 regulatory agencies. The exact way or manner of
16 implementation is to be left up entirely to these regulatory
17 agencies.

18 If our agency chooses to adopt the ICRP concept of
19 optimization, we are perfectly free to do so. But if we
20 choose to do it in some other manner, we are perfectly free
21 to do so. So is OSHA and DOE and all the others.

22 COMMISSIONER AHEARNE: I know what the
23 recommendation says, but that is not what the chart says.

24 CHAIRMAN HENDRIE: We have got a hand over here.
25 Let's see what the comment is.

1 MR. BAKER: I am Bob Baker from the regulatory
2 staff. As I understand it, and I am not an economist, but I
3 have been working with some of the international groups on
4 some of these concepts.

5 First, let's go back to justification.
6 Justification is a net benefit that can be shown from an
7 operation. In other words, one looks at the costs, the
8 benefits and there should be a net benefit. That is
9 justification.

10 The optimization, as I understand it, is simply
11 the differential of the cost/benefit equation. In other
12 words, one can take this differential and look at
13 alternatives. You have condition "A" and condition "B".
14 You now look at what are the costs from moving from "A" to
15 "B" and the benefits to be derived, including the changes in
16 the population collective dose, if you will.

17 The point is you have certain costs associated
18 with operations, certain benefits with operations, certain
19 detriments such as collective doses which may be expressed
20 in terms of an economic unit or monetary unit and there is
21 for optimization a very, I would use the word
22 "mathematically precise condition."

23 COMMISSIONER AHEARNE: I understand that. The
24 only issue I was trying to get at is the letter that we were
25 proposing to send to EPA said we agree with their approach.

1 It is an agreement with the ICRP recommendations. The chart
2 that was sent up indicates at least somewhere in the staff
3 here is a belief that there is a difference between the
4 two. It wasn't clear to me if (a) there was a difference,
5 and if there was, which side we came down on, and we ought
6 to at least when we go to EPA say if there is a difference
7 and which side to come down on.

8 MR. BAKER: I think generally speaking we are in
9 full agreement with them but we also recognize that the
10 actual implementation of a mathematically definitive
11 cost/benefit analysis is very difficult.

12 COMMISSIONER AHEARNE: Of course.

13 MR. BAKER: So we would use the elements in making
14 some judgments.

15 COMMISSIONER AHEARNE: Let me just ask a couple of
16 other minor questions.

17 Who regulates dental technicians?

18 MR. ALEXANDER: That is primarily done by the
19 states.

20 COMMISSIONER AHEARNE: The states would regulate
21 dental technicians.

22 How about X-ray technicians.

23 MR. ALEXANDER: The same.

24 COMMISSIONER AHEARNE: The same thing.

25 How about uranium miners?

1 MR. ALEXANDER: Miners, if you exclude the mills,
2 the minors are regulated by MSHA of the Department of Labor.

3 COMMISSIONER AHEARNE: Do they regulate on
4 radiation exposure?

5 MR. ALEXANDER: Yes.

6 COMMISSIONER AHEARNE: And Energy Department
7 workers?

8 MR. ALEXANDER: Well, Energy Department workers
9 and their contractors, the radiation exposures are
10 controlled by the Department of Energy itself.

11 COMMISSIONER AHEARNE: I was just trying to make
12 the point that there is a large bulk of high exposure people
13 that we don't reach.

14 The last question and this I notice has driven a
15 recent PN. Would you allow someone who wanted to get a job
16 who was 16 or 17, after you have explained the hazards, to
17 waive the one/tenth requirement?

18 MR. ARSINAULT: I don't think that is
19 anticipated. I would ask if anyone knows of any suggestion
20 that such a provision be included?

21 MR. ALEXANDER: There is a law against that. That
22 would not be a final decision for the NRC to make.

23 COMMISSIONER AHEARNE: There is a law against what?

24 MR. ALEXANDER: Against allowing a person under 18
25 years of age to receive more than one/tenth of the

1 permissible limits.

2 COMMISSIONER AHEARNE: There is a federal law?

3 MR. ALEXANDER: Yes. That has been on the books
4 for many years. That was the original basis of the AEC's ---

5 COMMISSIONER AHEARNE: So the one-tenth tracks
6 back to federal law?

7 MR. ALEXANDER: Yes.

8 COMMISSIONER AHEARNE: Bill.

9 MR. KREGER: I would just like to say that I think
10 the same thing applies to going one year below 19 that
11 applies to going one year over 50 if you are already at a
12 hundred rem. I don't think any of us think of those as
13 thresholds. There is no real difference between the risk of
14 five rim to an 18-year-old and the risk of five rem to a
15 19-year-old.

16 So, you know, if you applied logic you wouldn't
17 set a threshold at the upper end and you wouldn't
18 necessarily apply a threshold at the lower end.

19 COMMISSIONER AHEARNE: Those are all my questions.

20 COMMISSIONER GILINSKY: I don't follow that logic.

21 COMMISSIONER AHEARNE: The barrier that I just ran
22 into is that there is a law.

23 COMMISSIONER GILINSKY: Lawyers don't seem to know
24 about this law.

25 COMMISSIONER AHEARNE: Which law is it?

1 MR. ALEXANDER: It was originally in the Child
2 Labor Act when it was enacted. It has been changed now to
3 another law and I can't remember which one it is.

4 COMMISSIONER AHEARNE: I guess I would ask OGC to
5 do a little bit of legal research to track that down.

6 COMMISSIONER GILINSKY: I want to ask something
7 about notification. I wonder if it wouldn't make more sense
8 to have the notification apply when someone receives more
9 than two, three or four or however many rems in a particular
10 year, for him to be aware that he is increasing his
11 accumulated dose at a rate which if continued would get him
12 up to pretty high levels. If you set it at some
13 accumulative value then, as mentioned earlier, it comes at a
14 rather late point. It is not clear that it makes a lot of
15 difference.

16 COMMISSIONER AHEARNE: The choice a person may at
17 that stage have, you are being told now if you stay in this
18 job which you have been in for 20 years it is really going
19 to be hazardous.

20 COMMISSIONER GILINSKY: Yes, and the grim reaper
21 is coming after you pretty fast.

22 MR. ARSENAULT: If that comment was addressed to
23 me, it is in fact the position I hold.

24 COMMISSIONER GILINSKY: Well, I was addressing it
25 to Bob Alexander actually. I wonder if you have any

1 thoughts on that?

2 MR. ALEXANDER: I think that would be acceptable.
3 The alternative I suggested is nothing more than an
4 alternative. It is just based on the feeling that I believe
5 that these workers, and I particularly believe it after
6 traveling around the country and talking to people in the
7 course of these hearings, that these workers who are high
8 dose workers are not being informed. They are in a
9 different category than others who get low doses and I would
10 like to see our agency do something to turn that around.
11 Your idea is just as good as mine.

12 COMMISSIONER GILINSKY: You see, in order for
13 someone to reach the dose that you are talking about you
14 would have had to have gotten five or four or at least three
15 rems per year for many, many years and he would then have
16 been notified continually and also at an earlier point when
17 if he wants to he might want to become a test pilot or
18 become an iron worker or something way up in the sky.

19 MR. ARSENAULT: I would point out, if I may, that
20 since this is a matter of procedure and administration of a
21 radiation protection system, that the staff feels that it
22 should be a matter for regulation rather than guidance. It
23 need not be an EPA guidance. We would prefer to see the
24 opportunity reflected in the regulation.

25 COMMISSIONER GILINSKY: How is that again?

1 MR. ARSENAULT: That the matter of notifying the
2 worker concerning his level of exposure, whether it is some
3 threshold or routinely is ---

4 COMMISSIONER GILINSKY: Well, if we accept it we
5 would put into a regulation.

6 MR. ARSENAULT: --- a matter of procedure and
7 administration. It was a matter for regulation rather than
8 guidance was my point.

9 COMMISSIONER GILINSKY: Well, but on the basis of
10 their guidance we would write a regulation if we agreed with
11 it.

12 COMMISSIONER AHEARNE: Frank, the point I would
13 probably disagree with you on is that there are a number of
14 people that this guidance may speak to who may not feel as
15 you do. If we are providing comments I think it might be
16 useful for us to provide the comments at least in such a
17 useful way as to make it clear that we think that is really
18 a good thing to have in the implementing regulations of
19 whatever agency it is.

20 MR. ARSENAULT: Accepted.

21 CHAIRMAN HENDRIE: Peter?

22 COMMISSIONER BRADFORD: No.

23 CHAIRMAN HENDRIE: I guess the Commission ought to
24 indicate to the staff the direction.

25 COMMISSIONER AHEARNE: This is a letter for you to

1 sign.

2 CHAIRMAN HENDRIE: I must say my own inclination
3 is to go with the staff view. The majority view, I think is
4 overall a more rationally based system to try to sort out
5 the dose and exposure limits and their concentrations and so
6 on. Our best estimate of risk is to have the ALARA and
7 other considerations in another area where you can
8 distinguish between the two. I think there are a
9 considerable number of advantages to using the system which
10 is being reasonably consistent.

11 John?

12 COMMISSIONER GILINSKY: I have one more question.

13 COMMISSIONER AHEARNE: You have another question?

14 COMMISSIONER GILINSKY: Yes. One of the
15 recommendations that I think Bob Alexander made was that in
16 applying the system we now increase approved air
17 concentrations where there would otherwise be increased by
18 the ICRP guidance. What sort of problems would that pose if
19 we had a, so to speak, slightly mixed system? In other
20 words, if we kept the concentrations at present levels where
21 they would otherwise be increased and otherwise accept the
22 ICRP levels.

23 CHAIRMAN HENDRIE: Then you have done this mixing
24 of standards based on a equivalent risk level for various
25 isotopes and methods and types of exposure with other

1 considerations and you no longer have a system in which you
2 can neatly separate the equal risk elements in the places
3 you are hold them down just because it is reasonable and
4 practical to hold them down beyond the level with the
5 equivalent risk you suggest. That is why the majority view,
6 as I understand it, is not to do that but rather to separate
7 those two sorts of regulatory controls.

8 COMMISSIONER GILINSKY: Well, I understand that.
9 I am trying to get a feeling for just how bad that sort of
10 an approach would be. I mean, how much would it mess up the
11 neatness of just going with the ICRP?

12 CHAIRMAN HENDRIE: My impression is considerably.
13 It is going to lead to the kind of thing that Kreger was
14 talking about about a need to ask licensees for an
15 assortment of additional exposure condition data so you can
16 back calculate and come around to the risk equivalent
17 analysis.

18 COMMISSIONER GILINSKY: The other side of it is I
19 think you are going to be upsetting a lot of people who are
20 now subject to levels which would be increased. I guess I
21 don't know just how extensive this problem is or how many in
22 fact would be subject to higher levels.

23 CHAIRMAN HENDRIE: It is not clear that the levels
24 would be increased.

25 COMMISSIONER GILINSKY: I thought some of them

1 would be.

2 CHAIRMAN HENDRIE: What would be increased would
3 be limiting values in a NRC table. When you get into a
4 particular plant and they say now what is going to work
5 here, why then the ALARA side at least in principle could
6 very well hold you down where you were below.

7 COMMISSIONER GILINSKY: Well, you are saying the
8 doses may not increase.

9 CHAIRMAN HENDRIE: Yes.

10 COMMISSIONER GILINSKY: There is a letter in one
11 of the attachments that we have been seeing that expresses
12 some concern about this. Anyway, how big a problem is it?

13 MR. ARSENAULT: I do want to emphasize that the
14 staff's position does not imply that it is in favor of
15 increasing either limits or exposure.

16 COMMISSIONER GILINSKY: Well, you would be
17 increasing limits.

18 MR. ARSENAULT: Yes, you would be increasing the
19 limits that are applied by the radiation protection guides.
20 There are additional limitations that arise out of the
21 application of ALARA. I think, as Chairman Hendrie has
22 pointed out, both are applied and the application of a
23 system that results in increased radiation protection guides
24 limits on occupational exposure doesn't necessarily mean
25 that the experience in the work place would change. So that

1 is important.

2 COMMISSIONER GILINSKY: Right, but it might.

3 MR. ARSENAULT: But it might.

4 Now to address more explicitly the question you
5 asked. Introducing limitations that are not based on risk
6 equivalents would, and I may ask for more detailed technical
7 assistance on this one as well, but it would result in a
8 change in the significance of the exposure as recorded for a
9 particular worker. This arises out of the way in which the
10 doses are calculated from the exposure of the worker to the
11 concentrations of the radionuclide in the air. It is a
12 matter of the way in which these ---

13 COMMISSIONER GILINSKY: Well, I realize there will
14 be some change, but given the isotopes that are involved in
15 what you know of the various industries do you have any
16 sense of how big an impact they would be and how much it
17 would upset the neatness of our scheme because, on the one
18 hand, you know, there is something to be said for having
19 sort of a neat match with the rest of the world and, on the
20 other hand, we are trying to protect workers in this country
21 and it is not small thing to relax the standards to
22 subjective.

23 MR. ARSENAULT: Well, it impacts the coherence of
24 the system. Maybe saying that it destroys the coherence of
25 the system might carry too big an impact. It does

1 significantly impact the coherence of the system.

2 COMMISSIONER GILINSKY: You don't like the idea I
3 gather.

4 (Laughter.)

5 MR. ARSENAULT: I don't. We went into this at
6 some length when we discussed exactly the same problem in
7 connection with the EPA limitation. Having established a
8 coherent system for calculating limits they then imposed a
9 totally arbitrary system on top of that which says the lower
10 of two values will be chosen. This impacts your ability to
11 use that system in the way it was designed to be applied.

12 COMMISSIONER GILINSKY: Could we hear from Mr.
13 Alexander on that point.

14 MR. ALEXANDER: The only think I could like to say
15 is I think I have been influenced quite a lot by the labor
16 union people that I have talked to. As a health physicist
17 the ICRP system based on a summation of risks is very
18 appealing and I would like very much to see it established
19 and I wish we had had it all of these years.

20 On the other hand, a fellow who is going to be
21 asked to breathe more radioactivity uses terms like
22 ridiculous in connection with our desires. So I am afraid I
23 lean toward the fellow that has to breathe the
24 radioactivity. I have breathed quite a bit of it myself. I
25 think that the price that we have to pay to adopt the ICRP

1 system in total is too great.

2 MR. ARSENAULT: I can only add to that that if we
3 believe the level of radioactivity being breathed by the
4 worker is unjustified, then it is up to us to achieve a
5 lower level based on the application of the principles
6 embedded in our current regulations. If those levels are
7 too high then the condition at that particular licensee is
8 not ALARA.

9 COMMISSIONER GILINSKY: Everything is for the best.

10 MR. ALEXANDER: Commissioner Gilinsky, if I might
11 make one more point. I believe if the Commission had a good
12 tight way of making the ALARA concept inspectable and
13 enforceable that I wouldn't have this concern.

14 COMMISSIONER GILINSKY: What you are saying is if
15 in practice one could keep the doses down even though some
16 of the limits were relaxed it would be an acceptable scheme?

17 MR. ALEXANDER: Yes, because if these plants are
18 operating at the levels they are right now and have been in
19 an economically acceptable manner for many years then they
20 have proven by experience that is ALARA to do so.

21 So if we had an inspectable and enforceable ALARA
22 program then they wouldn't be allowed to increase. With
23 what we have right now I don't think we can do that. I
24 don't think we can count on what we are doing about
25 occupational ALARA to keep these concentrations down.

1 COMMISSIONER AHEARNE: We had a proposed rule that
2 was being worked over the last six months or so. What is
3 the status of that? That would be to put in place an ALARA
4 program, an inspectable ALARA program.

5 MR. ALEXANDER: Well, we have run onto some
6 difficulty with respect to staff resources in implementing
7 what we had originally proposed and we are meeting with MNSS
8 personnel right to try to develop a slightly alternative
9 regulation than we one we had proposed in SECY 81-86. It
10 should be ready within a few weeks.

11 COMMISSIONER AHEARNE: If that were to be put in
12 place would that be the kind of a program that you were
13 talking about?

14 MR. ALEXANDER: No.

15 COMMISSIONER AHEARNE: That is not right enough.

16 CHAIRMAN WENDRIE: Go ahead, Bill.

17 MR. KREGER: Could I have a rebuttal for a
18 minute. I think the implication that Bob made that we don't
19 have an inspectable and enforceable ALARA program is a false
20 implication.

21 COMMISSIONER AHEARNE: It wasn't an implication.
22 It was a statement.

23 MR. KREGER: Is a false statment. We have made
24 great strides in the last five years. We issued recently
25 NUREG 0761 which proposes the radiation protection plan that

1 will be implemented for reactor licensees by insertion into
2 the technical specification. That plan will be going
3 forth. The comment period ends on the 30th of June. We
4 expect to issue that plan as a final statement this summer
5 with letters to all licensees in accordance with the
6 Commission's indication that they felt that was an
7 appropriate way to go for reactors.

8 I do believe that with that in place and with the
9 things that have been imposed because of the health physics
10 appraisal program at all operating reactors that there will
11 be a great deal of improvement in the ALARA implementation
12 at operating reactors.

13 I don't believe that any worker has to fear that
14 he is going to be exposed because of one raise or several
15 raises in a particular ELI or whatever that he will be
16 forced, as Bob implied, to breathe more radiation.

17 COMMISSIONER AHEARNE: I&E rises in defense of the
18 inspection program.

19 MR. THORNBURG: I think I would intend to agree
20 with Bill. ALARA at this point is not the easiest concept
21 in the world to enforce because the limits aren't rigid. I
22 think that we have made a lot of strides in our health
23 physics appraisal program and generally in the rest of our
24 inspection program. We have been inspecting the standard
25 for the last several years.

1 We haven't had major conflicts with everyone we
2 have dealt with. We have had some problems. Generally I
3 wouldn't say that it is a toothless thing. I think that
4 there has been some positive impact.

5 MR. ARSENAULT: I just wanted to point out in
6 connection with this issue that in the ICRP 26 and the EPA
7 proposed guidance ALARA is treated in the sense of it
8 becoming a requirement and that is likely to lead to a
9 somewhat more rigorous approach to the issue as well.

10 I don't want to suggest that all of the problems
11 that we have been discussing will be resolved by that, but
12 it will be a mandatory requirement at that point.

13 CHAIRMAN HENDRIE: For an ALARA program.

14 MR. ARSENAULT: For an ALARA program.

15 We do also a second minority viewpoint ---

16 CHAIRMAN HENDRIE: We had better hear that.

17 MR. ARSENAULT: --- which is perhaps less complex
18 than this one. If I might summarize it, I think Charlie
19 Willis is with us and could address it in detail, if you
20 wish.

21 His point is that the change to any new system at
22 this point involves significant costs for the licensee and
23 that there is no justification and benefits to be derived
24 for the workers in this change.

25 In view of the fact that the new limitations are

1 likely to impact only a few workers, and most now are
2 covered by ALARA programs are receiving exposures well below
3 either the new or the old limits, his argument at least
4 represents a valid point of view, that the benefits overall
5 don't necessarily justify the costs involved. That is as
6 succinct as I can summarize his position.

7 The majority staff position has been made clear in
8 the discussion so far. As it plays up against this
9 viewpoint I would add one more observation, and that is that
10 the evolution of the regulatory process appears to be in the
11 direction of using risk as a more explicit basis for its
12 decision making, and that a system which allows for
13 comparative assessments of risk is going to be one that
14 serves the purposes of that system better than the one that
15 now exists.

16 On the basis of that viewpoint, it seems to be
17 that the adoption of a system with characteristics like
18 either the EPA or the ICRP system is inevitable and it is
19 bound to be cheaper to adopt it earlier.

20 COMMISSIONER AHEARNE: Does Mr. Willis agree with
21 your summary description?

22 MR. ARSENAULT: Well, unless I have garbled it
23 since last I talked to him, I think he believes it is a fair
24 but succinct statement.

25 COMMISSIONER BRADFORD: His hand is up.

1 MR. WILLIS: I am Charlie Willis, NRR. What Frank
2 as said is pretty well a restatement of my position. There
3 are a couple of amplifications I would like to make.

4 One that goes kind of counter to several of the
5 asides that we have heard today is the idea that if one
6 wanted to transfer from radiation work to a more hazardous
7 profession he might become a test pilot or a farm machinery
8 operator or something that is really dangerous. I think
9 that is counter to all the data that we have.

10 As far as we know if a man transferred from
11 radiation work to the average job in the United States his
12 exposure to carcinogens would increase. In other words, we
13 have controlled radiation better than we have the average
14 carcinogen rate. The exposure of a politician to a
15 smoke-filled room, if you will, could be more dangerous than
16 the radiation. So I am starting from a position that if it
17 ain't broke don't fix it.

18 The other corollary here is that the ICRP 26
19 position is not quite as solid in my view as it has been
20 presented. Most countries of the world can pay and do pay
21 lip service to this without actually doing it.

22 We heard from our British friends a comment
23 yesterday that I thought I was instructive talking about the
24 requirement for measuring very low systemic burdens of
25 actinides. Yes, we know it probably can't be done, but that

1 is no reason for not requiring it. Well, I think that would
2 be a reason for not requiring it in this country.

3 The fundamental approach of basing your limits on
4 risk is a difficult one, not because the ICRP hasn't spelled
5 out their risk estimates, but because risk estimates change
6 with every new measurement. We certainly don't change the
7 speed limits every time we get another measurement of the
8 coefficient of friction of rubber on concrete and this is
9 what we are doing.

10 You are talking about the question about the doses
11 at Hiroshima and Nagasaki. That is just one indication of
12 the kind of problem we have with changing risk estimates.
13 They will change every few years.

14 We had a running risk estimate that we used
15 finally and the Beir Committee in '71 or something came out
16 with a refined set of risk estimates. Very shortly
17 thereafter the NRC staff came out with the GESMO. We felt
18 that we had to develop new risk estimates because things had
19 been learned and now we have come out with Beir Three. They
20 have a new set of risk estimates which don't agree with the
21 ICRP. We now have the flap about the doses that the risk
22 estimates were based on.

23 So if we do this, if we base our regulations on
24 risk, we are going to have a highly unstable industry and
25 that does not seem like good business to me.

1 Finally, if you report things in terms of risk
2 rather than doses to specific organs, you lose a great deal
3 of information. It makes a tremendous difference from a
4 epidemiological standpoint whether a person received "X" rem
5 to the bone or whether he received "Y" rem to the whole body
6 even though they turn out to give you the same total risk.
7 So basing regulation on risk is not an unquestionable
8 virtue.

9 Finally, my concern is, and really the concern of
10 the whole thing and why I am embarrassing myself is that I
11 feel that the Commissioners are being placed in a position
12 of being asked to sign a letter that says we buy ICRP 26
13 without getting a full evaluation of ICRP 26.

14 If this happens and we the staff start working on
15 this problem next week, then the acceptance of ICRP 26 is a
16 given. That is no longer debatable. The Commissioners have
17 approved and this does not seem like the wisest way to do
18 business in my opinion.

19 Thank you.

20 COMMISSIONER GILINSKY: Before you leave let me
21 ask you a question. In saying that you don't want to tie
22 the regulatory requirements to risk, you seemed to be
23 concerned about varying requirements. Now, clearly there is
24 something to be said for keeping them stable and not
25 changing them every year. But at the time you do fix

1 them ---

2 CHAIRMAN HENDRIE: Or set them originally.

3 COMMISSIONER GILINSKY: Right, or set them
4 originally, I would think you do want to relate them to risk.

5 MR. WILLIS: The limits that we have now are in a
6 sense related to risk, or at least related to the estimates
7 of risk that we had in '58. But the way we require things
8 to be reported now in terms of body doses and external
9 doses, et cetera, is such that we can revise the risk
10 estimate each time the basis for risk evaluations change.
11 If we simply had one number there wouldn't be anything we
12 could do with it. As the risk estimates change now the
13 limits do not change.

14 So far all of our risk estimate changes have been
15 in a fairly narrow range so that changing limits probably
16 isn't justified, at least not on the basis of protecting the
17 workers in my opinion anyway, and I think that is consistent
18 with what the NCRP people tell me and so forth.

19 The NCRP, by the way, as you well know, is the
20 national organization whose job it is to clarify and endorse
21 the ICRP recommendations as they would like to see them
22 apply to this country. The NCRP has not endorsed ICR. 26,
23 and in fact the NCRP is busy working up their own set of
24 risk estimates that will be different again.

25 COMMISSIONER GILINSKY: Thank you very much.

1 MR. WILLIS: Thank you.

2 COMMISSIONER AHEARNE: I guess I will probably
3 want to at least think through a little of this for a day.
4 I will file a vote sheet with my comments. I would hope
5 that if the Commission itself can't reach a decision on the
6 comments to send that EDO would send comments at least
7 because as I understand it July 6th is the deadline. I
8 think that since the NRC is such a major participant in this
9 we ought to get our comments, either hopefully the
10 Commission's comments but at least EDO's comments, sent.

11 CHAIRMAN HENDRIE: I certainly agree with that.
12 If you want to hold off and give an indication by notation,
13 why that is fine with me.

14 Vic?

15 COMMISSIONER GILINSKY: I want to think about it.

16 CHAIRMAN HENDRIE: Okay.

17 Any final comments?

18 (No response.)

19 CHAIRMAN HENDRIE: Thank you very much.

20 (Whereupon, at 4:15 p.m., the meeting adjourned.)

21

22

23

24

25

NUCLEAR REGULATORY COMMISSION

This is to certify that the attached proceedings before the

in the matter of: BRIEFING ON SECY-81-232 - COMMENTS ON THE EPA-PROPOSED
GUIDANCE FOR OCCUPATIONAL EXPOSURES

Date of Proceeding: June 10, 1981

Docket Number: _____

Place of Proceeding: Washington, D.C.

were held as herein appears, and that this is the original transcript thereof for the file of the Commission.

Mary C. Simons

Official Reporter (Typed)

Mary C Simons

Official Reporter (Signature)

SUMMARY OF DIFFERENT OCCUPATIONAL RADIATION PROTECTION GUIDELINES

	A	B	C	D	E	F	G
	EPA Proposed Guidance	ICRP-26 Recommendations	HRC Current Part 20	Staff Majority (1) SECY-01-232	Staff Majority (2) SECY-01-232	Staff Minority (1) SECY-01-232	Staff Minority (2) SECY-01-232
1. Justification	required	required (plus cost-benefit alternatives)	required	does not address	accept new guidance	not addressed	Retain D*
2. ALARA	required	required including collective dose	required including optimization	mandatory rule (non-specific)	accept ICRP-26	not addressed	Retain D*
3. Dose Limits (a) Whole body	5 rems/yr plus 5(R 10)	5 rems/yr (combined external and internal on risk equivalent basis)	5 rems/yr (combined external and internal on risk equivalent basis)	1.25 rems/yr or 3 rems/yr plus 5(R 10) (external radiation; internal doses not additive)	same as ICRP-26	5 rems/yr 3 rems/yr	Retain D*
(b) Partial Body	critical organ limits	limit on sum of organ risks, plus 50 rem cap; excludes gonads (if values different from ICRP-26)	limit on sum of organ risks, plus 50 rem cap; includes gonads (if defined)	limits on intake; critical organ limit basis	same as ICRP-26	same as new guidance	Retain D*
(c) Combined Ext. and Internal	Independent Limits	combined limits	combined limits	Independent Limits	combined limits	combined limits	Retain D*
4. Radiation Protection Requirements	not specified	limits given in three ranges, would include 100 rem lifetime limit.	reference levels given in three ranges, no lifetime limit.	specified in Part 20 or licenses, no lifetime limit.	omit from new guidance; but reflect in revised Part 20 (opposes career limitation)	notification of high-dose workers when risk reaches pre-set level.	Retain D*
5. Concentration Values Lower Than DAC's or MPC's	does not address	would collect lower of old or new values for existing or similar operations	ALARA Issue	does not address	ALARA Issue; delete from guidance; use ICRP-26 and ICRP-30	same as new guidance	Retain D*
6. Limits Lower Than RPG's for Specific Job Categories	does not address	recommended	ALARA Issue	does not address	ALARA Issue; omit from new guidance	omit from new guidance	Retain D*
7. Minors	1/10 RPG's	1/10 RPG's	no specific guidance	1/10 adult limits	1/10 adult limits	1/10 adult limits	Retain D*
8. The Public	not addressed	four alternatives given for comment	specific: 5 rems/yr, recommend: 1.5 rems/yr	not addressed (Req. Guide recommends informed consent)	Informed consent	Informed consent	same as majority
9. Exceeding RPG's	permitted at discretion of regulatory agency	permitted, public disclosure required	twice the annual limit per event, five times this limit in a lifetime	no provision other than 5(R 10) rule	same as ICRP-26	same as ICRP-26	Retain D*

	A	B	C	D	E	F	G
	HR 1060 Current Guidance	EPA Proposed Guidance	ICRP-26 Recommendations	NRC Current 10 CFR 20	Staff Majority SECY-81-232	Staff Minority (1) SECY-81-232	Staff Minority (2) SECY-81-232
1	Exclude base group and medical radiation	comparable provision	comparable provision	comparable provision	comparable provision	not addressed	Retain D *
2	Summation of internal effective dose commitment to be applied to all body parts	required (weighting factors different from ICRP-26)	required	not required	same as ICRP-26	modified	Retain D *
3	Current ICRP quality factors and dose factors to be used for current laws	accept current values	accept current values	old ICRP values	accept current values	accept current values	Retain D *
4	Binary total equivalent limits	not provided	not provided	not provided	not provided	not provided	not provided
5	Procedures for handling overexposure	not provided	recommends establishment of provisions	addressed in 10 CFR 20 Statement of consideration	same as ICRP-26	not addressed	not addressed
6	Base limits for protons, other than one year	1 rem/yr, plus 5/10 (External)	not addressed	1.25 rem/yr, or 3 rem/yr, plus 5/10 External exposure	not addressed	quarterly limits	Retain D *
7	Existing guides for limiting exposure of uranium miners	not changed	RRG apply to all workers	not addressed (HR does not regulate miners)	not addressed	not addressed	not addressed

* Retain present limits, and regulation unless justification (cost/benefit) is provided

PROPOSED EPA GUIDANCE

1. JUSTIFICATION OF EXPOSURES BY NET BENEFIT. CONSIDERATION OF NON-
RADIATION ALTERNATIVES

2. ASSURE THAT COLLECTIVE DOSES ARE ALARA

PROPOSED EPA GUIDANCE

3. DOSES TO CONFORM TO RADIATION PROTECTION GUIDES (RPG's)

A. EFFECTIVE DOSE EQUIVALENT FROM INTERNAL AND EXTERNAL EXPOSURE -

5 REM PER YEAR.

B. NON-UNIFORM EXPOSURE (ORGAN) ALSO HAS TO SATISFY THE ABOVE CONDITION

ON RISK EQUIVALENT BASIS.

ADDITIONAL LIMIT - 30 REM TO SINGLE ORGAN (GONADS - 5 REM)

RECOMMENDED ORGAN WEIGHTING FACTORS DIFFERENT FROM ICRP-26

PROPOSED EPA GUIDANCE

4. 3-TIER SYSTEM OF GRADED RADIATION PROTECTION ACTIONS

4A. 100REM LIFETIME DOSE LIMIT

5. ESTABLISH "RADIOACTIVITY INTAKE FACTORS" (RIF'S) TO MEET RPG'S

5B. IF RIF HIGHER THAN CURRENTLY IN USE (MPC) ADOPT CURRENT VALUE

PROPOSED EPA GUIDANCE

6. ESTABLISHMENT OF LIMITS BELOW RPG'S AND RIF'S

7. LIMIT OF 1/10 RPG FOR MINORS

8. EXPOSURE LIMITS FOR THE UNBORN (4 ALTERNATIVES FOR COMMENT)

9. SPECIAL PLANNED EXPOSURES EXCEEDING RPG - DISCLOSURE REQUIREMENT

COMPARISON OF EPA'S PROPOSED GUIDANCE WITH
1960-FRC GUIDANCE AND CURRENT 10 CFR PART 20

EPA - COMBINED EXTERNAL AND INTERNAL DOSE LIMIT - 5 REM/YR

VS POSSIBLE 12 REM/YR EXTERNAL PLUS 15 REM (OR 30) FROM
INTERNAL EXPOSURE TO INDIVIDUAL ORGANS

EPA - 100 REM LIFETIME LIMIT

VS 5(N-18)

DIFFERENCES BETWEEN EPA GUIDANCE AND ICRP-26 RECOMMENDATIONS

1. DIFFERENT ORGAN WEIGHTING FACTORS

2. NON-STOCHASTIC ORGAN DOSE LIMIT: EPA - 30 REM
ICRP = 50 REM

3. GONADS: EPA - SEPARATE LIMIT - 5 REM/YR
ICRP - INCLUDED IN CALCULATIONS
OF EFFECTIVE DOSE EQUIVALENT

4. LIFETIME LIMIT: EPA - 100 REM
ICRP - NO LIFETIME LIMIT

RECOMMENDED ORGAN WEIGHTING FACTORS |

TISSUES	WEIGHTING FACTORS (Wt)	
	EPA	ICRP
GONADS	-	0.25
BREAST	0.20	0.15
RED BONE MARROW	0.16	0.12
LUNG	0.16	0.12
THYROID	0.04	0.03
BONE SURFACES	0.03	0.03
SKIN	6.01	-
REMAINDER (OTHER ORGANS)	0.40	0.30

STAFF RECOMMENDATIONS (MAJORITY)

1. ACCEPT ICRP-26 SYSTEM OF DOSE LIMITATION
2. NO CAREER DOSE LIMIT
3. OMIT ALARA ISSUES FROM GUIDANCE
4. PROTECTION OF THE UNBORN BASED ON INFORMED CONSENT

STAFF RECOMMENDATION (MAJORITY)
RADIOACTIVITY INTAKE FACTORS - ANNUAL LIMITS OF INTAKE (ALI)

ACCEPT ICRP-26, ICRP-30 ALI'S

1. ICRP SYSTEM GENERALLY MORE RESTRICTIVE THAN CURRENT STANDARDS
2. SOME DERIVED AIR CONCENTRATIONS (DAC'S) HIGHER THAN CURRENT MPC'S
IN 10 CFR PART 20
3. DAC'S AND MPC'S NOT DIRECTLY COMPARABLE
4. DAC'S BASED ON CONTEMPORARY SCIENTIFIC DATA AND EQUIVALENCY OF RISK
5. DERIVED LIMITS RESULTING FROM SCIENTIFICALLY BASED COHERENT SYSTEM
SHOULD BE USED, WHETHER THEY ARE HIGHER OR LOWER
6. ALARA CONSIDERATION MIGHT DICTATE OPERATION BELOW DAC'S

IMPLEMENTATION OF ICRP-26 SYSTEM OF DOSE LIMITATION

1. SIMPLIFIED EXTERNAL AND INTERNAL SUMMATION PROCEDURES FOR LICENSEES MEETING SPECIFIED EXPOSURE CONDITIONS
2. SPECIFIC GUIDANCE RE: SUMMATION TO BE PROVIDED BY NRC FOR OTHER LICENSEES
3. 5⁰ YEAR COMMITTED DOSE FROM INTERNAL EXPOSURE CHARGED TO PERIOD OF INTAKE - NO CHANGE FROM CURRENT 10 CFR PART 20

SIGNIFICANCE OF IMPLEMENTATION COSTS

ISSUE	EPA GUIDANCE	STAFF MAJORITY
1. JUSTIFICATION	MINOR	MINOR
2. ALARA	SIGNIFICANT	SIGNIFICANT
3. DOSE LIMITATION	SIGNIFICANT ON IMPLEMENTATION AND IN THE FUTURE (DIFFERENT SYSTEM FROM THE REST OF THE WORLD)	SIGNIFICANT BUT MUCH LESS THAN EPA GUIDANCE
4. RADIATION PROTECTION REQUIREMENTS	SIGNIFICANT	MINOR
5. LIMITS LOWER THAN DAC'S	SIGNIFICANT	MINOR
6. LIMITS LOWER THAN RPG'S FOR SPECIFIC JOBS	SIGNIFICANT	MINOR
7. MINORS	NONE	NONE
8. THE US BORN	???	MINOR
9. EXCEEDING RPG'S	MINOR	MINOR

REVISED DOSE ESTIMATES

HIROSHIMA AND NAGASAKI

1. DATA PRELIMINARY - PREMATURE TO DRAW QUANTITATIVE RISK ESTIMATES
2. IF REVISED DOSE ESTIMATES CORRECT, MINOR IMPACT (ON THE ORDER OF TWO) ON ESTIMATES OF RISK FROM LOW LET RADIATION
 - A. RISK ESTIMATES BASED NOT ONLY ON JAPANESE DATA
 - B. LINEAR DOSE RESPONSE RELATIONSHIP APPLIED TO ESTIMATE RISK FACTORS USED IN RADIATION PROTECTION STANDARDS